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Abstract 
 
In this present study changes in nanoparticles motion were explored in the presence and the 
absence of G-blocks in mucus matrices such as; porcine gastric mucus (45 mg/ml), and a 
mixture of porcine gastric mucus + polymeric mucus (non-degraded mucin from porcine 
stomach (45 mg/ml) respectively. 
These mucus types were tested to determine nanoparticle motion in their mesh networks, in 
order to deepen the understanding of nanoparticle motion behaviors in these complex 
biological environments, clarify the involvement of mucus components as motion barrier to 
nanoparticle diffusion, as well as identify the exciting challenges for nanoscale drug delivery. 
Multiple particle tracking technique was used to image movements of amine and carboxylate 
modified nanoparticles in mucus samples precisely by a series of experimental design.  
Nanoparticles exhibited sub diffusive motion in mucus samples, which is a common behavior 
of nanoparticle in mucus matrix, however, there were other types of nanoparticle motion 
modes seen in samples; diffusive (nanoparticle display increased motion with time scale), 
immobile (nanoparticle could not move with increasing time scale), and hindered motion 
(nanoparticle could not move further in mucus with increasing time scale and show vibrating 
motion). 
It was found that, nanoparticle motion is dependent on mucus components presented in 
mucus mesh. A significant increased on nanoparticle motion was identified in porcine gastric 
mucus mixed with polymeric mucus (45 mg/ml) compared to nanoparticle motion in sigma 
porcine mucus which not subjected to mixture with polymeric mucus (45 mg/ml). 
It was stated that, polymeric mucus makes more pores or either provides a scaffold in mucus 
network which results in increased nanoparticle motion.  
A shift toward greater nanoparticle motion at longer time scales confirmed the ability of G-
blocks to improve nanoparticle diffusion. It is apparent that high levels of G-blocks may 
collapse all the structure and increase the mucus barrier. In addition, nanoparticle motion is 
dependent on the surface chemistry which determines the degree of interaction with the 
mucus components and mucus barrier disruption.  
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The apparent barriers to particle motion vary with time scale. At short timescales movements 
on short distance are shown. 
Trajectory patterns at short time scales could reflect particle interaction with the matrix 
architecture or moving within network pores but are unlikely to show particles crossing 
matrix pore elements. 
A key success in nanoparticle transport is to avoid adhesive interaction within mucus 
components. Results of this study indicate that, G-blocks have enough potential to engineer 
nanoparticle in order to traverse mucus matrix and reach targeted sites in the body. 
Reduction of barrier properties of the mucus layer would be associated to G-blocks ability to 
alter mucus rheology in a favorable manner to uptake nanoparticle. 
Whether the barrier is decresed or increased by G-blocks depends on amount of G-blocks, 
Nanoparticle surface, addition of G-blocks in mucus matrix, as well as time scale. 
Such an improvement in nanoparticle transport through mucus blanket can lead to innovative 
drug delivery system for site specific target drug release, in order to combat against 
respiratory disease in particular cystic fibrosis disorder. 
The data presented here may be consistant with a model where G-blocks alter the mucus 
barrier architecture. This study must be repeated in ex vivo native matricses because it has 
been clearly shown here that the matrix components is critical to the barrier properties.                   
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Chapter 1 
Introduction 
Aim of thesis-Motivation 
 
The aim of this master thesis was to investigate barrier properties of mucus to nanoparticle 
movement and the way in which G-blocks alter these barrier properties. The mucosal surfaces 
of the gastrointestinal, respiratory and genitourinary tracts are major targets for drug delivery 
and effective drug delivery at these sites involves drug transport across secreted mucus.   
Mucus is a highly hydrated network of polymeric mucin molecules where the pores in the 
network additionally contain other biopolymers, which may or may not form non covalent 
associations with the mucin matrix.  Traditionally mucus has not been considered a major 
barrier to drug delivery, and it does not generally present a significant hindrance to the 
passage of small drug molecules.  However, new trends in drug development have led to 
increasing interest in the use of biological macromolecules, such as proteins, and polymeric 
or colloidal carrier systems, such as in gene delivery, and for these classes of pharmaceuticals 
mucus can present a significant barrier to uptake. 
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1.1 Mucus 
1.1.1 Physiology 
 
Mucus is a viscoelastic bio-gel that provides a semipermeable protective coverage to surfaces 
of the body tissues not supported  by skin, such as those respiratory, gastrointestinal (GI), 
female reproductive tract, and the surface of the eye [1].  
The semipermeable property of mucus network allows the exchange of nutrients, water, 
gases, odorants, hormones, and gametes, while being impermeable to most foreign particles, 
bacteria and pathogens [2, 3]. 
Mucus is one of the body’s first defenses against infection by preventing pathogen access the 
epithelial surface [4]. 
Mucus provides a wet layer over epithelium tissue to minimize the friction between organs, 
and lubricate the surfaces [5, 6]. Importantly, mucus secretion protects the stomach from the 
chemical action of its own gastric juice [7].  
Mucus gel is secreted and transported continually before being digested or shed in epithelial 
surface. The body produces nearly 10 l (2.5 gal) of mucus gel each day which is digested and 
recycled or released in feces, sputum, salvia, and nasal secretions, reproductive tract 
secretion, and tears (Figure 1.1) [2]. 
In human GI tract, the mucus layer is thickest in the stomach (180 µm; range 50-450 µm) and 
colon (110-160µm). In the small intestine, the mucus thickness can change greatly based on 
digestive activity stimulated by diet (Figure 1.1) [2]. 
The thickness of mucus gel is dominated by the balance between the rate of secretion and rate 
of degradation and shedding. Toxic and irritating substances can greatly stimulate mucus 
secretion, increasing the thickness of mucus blanket and facilitating irritants removal form 
epithelial surface [2]. 
In respiratory tract, mucus performs its regulatory functions by continuously moving, and 
trapping particulates on airways surfaces. Mucus function is supported by ciliated epithelial 
cells, which form the mucociliary escalator alongside cough, in order to maintain sterile 
     Mucus barrier components, challenges for nanoscale drug delivery 
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airways system. The mucus layer is much thinner (averaged 15 µm) in respiratory tract than 
GI tract and cilia motion removes particles by mucus clearance (Figure 1.1) [2, 5]. 
 
                         
          Figure 1.1: General characteristics of the mucus gel on epithelial surfaces [2]. 
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Mucus clearance time, blanket thickness, and pH can differ based on its anatomical location 
on epithelial surfaces (Figure 1.2) [8]. 
 
   
 
 
Figure 1.2: Mucus layer in different epithelial surfaces based on its anatomical location. 
Epithelial cells from different anatomical locations are drawn here in the same size. Mucin 
polymers coated all wet epithelia which serve as protective gel (shown in blue). Mucus 
features such as thickness, clearance time and pH, as well as total surface area of epithelial 
surfaces are present in figure [8]. 
 
 
 
 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
  5 
 
1.1.1.1 Mucus function in mucociliary clearance system 
 
In the mammalian lung, mucus performs its protective function by trapping and removing a 
wide variety of toxic substances and invading pathogens from the airways surfaces. Mucus 
layer and a periciliary layer (PCL) are two components of the clearance system that has 
recently described as gel-on-brush model (Figure 1.3) [9, 10].  
The mucus gel layer traps particles and is propelled out of the lung by cilia beat which 
generating the required forces for particle removal. The periciliary layer (a liquid-filled 
domain) is occupied by membrane-spanning mucins and large mucopolysaccharides that 
cooperating with cilia, microvilli, and epithelial surface, in order to maintain a favorable 
environment for cilia beating and cell surface lubrication (Figure 1.3) [9]. 
Failure in this system causes mucus build up and breathing problems which appear for 
example in patients with chronic obstructive pulmonary disease (COPD) and cystic fibrosis 
(CF). Both diseases are accrued by dehydrated airways mucus with mucin and globular 
protein concentrations several times higher than in normal mucus, while in healthy 
individuals without lungs disease the inhaled particles are transport out by sticky mucus and 
cilia propulsion [9]. 
                
Figure 1.3: Schematic representation of mucus structure by gel-on-brush model [10]. 
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1.1.2 Mucus biochemistry and structure 
1.1.2.1 Mucin 
 
Mucin polymer is the main gel-forming molecule of mucus. Mucins are high molecular 
weight glycoprotein (10 6- 10 7 Da) that contains protein backbone which are highly O-
glycosylated. Thus, mucin polymer composition is dominated by carbohydrates, which 
making up to 80 % of the dry weight of the molecule (Figure 1.4) [11]. 
Mucin polymers are enriched in the amino acids serine and threonine, which form the protein 
backbone with sugars linkages including; N-acetylgalactosamine, galactose, and fucose. In 
addition, mucin polymer contains sialic acids and sulfates, making mucins negatively charged 
at physiological pH (Figure 1.4) [11, 12]. 
As shown in Figure 1.4, mucin subunit is a rod-shaped molecule which composed of a linear 
polypeptide core of 100,000 <Mw<250,000 g mol -1 in center with o-linked chains of 2 to 12 
monosaccharaide residues. Mucin are polymerized N-N, C-C, to form mucin polymers [11]. 
Mucin polymers are relatively resistant to proteases due to high degree of glycosylation, 
making the protein backbone less accessible to enzymatic hydrolysis and resulting in a more 
robust mucus layer in mammalian organs [11]. 
Hydrated mucin polymers associate non-covalently form a gel matrix that is around 95 % 
water. The negative charges on mucins mean the fibers in the mucus matrix repel each other 
and prevent mucin aggregate and gel collapse.  
                                
                       Figure 1.4: Schematic structure of the mucin polymer [11]. 
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The multifunctional glycoproteins in mucus prevent barrier dehydration and are the major 
determinant of proper functionality. The condensed and complex microstructure of the mucus 
network gives rise to a heterogeneous bio-gel [13].  
Mucus structure can be investigated by scanning electron microscopy (SEM) technique, to 
image the mucus network. SEM images show 3 dimensional networks of mucin fibers with 
varying pore sizes and pore size distributions. Images from various mucus preparation show 
broad similarities (Figure 1.5) [14]. 
              
Figure 1.5: SEM pictures of different mucus layers. Scanning electron microscope (SEM) 
images of the mucus matrix formed by different type of mucins. (a) Presents porcine stomach 
mucus layer with porous mesh up to 0.9 µm in diameter, (b) the matrix of the bovine sub 
maxillary layer formed of porous network up to 0.4 µm, (c) Human salivary mucin with mesh 
size of 0.8 µm in diameter [14]. 
M-C Lavaud and co-workers have also shown varying thicknesses of mucin filaments within 
the matrix. Thinner filaments linked together thicker filaments measuring between 300 and 
400nm. The intermediate filaments varied between 100 and 200nm. Very thin and sparse 
filaments crossed the meshes, measuring between 10 to 100nm. They also saw Spermatozoa, 
bacteria and unspecified round cells were enmeshed in the mucus (Figure 1.6) [15]. 
                            
Figure 1.6: Structural features of cervical mucus (d), and nasal (e) mucus. The filaments 
measuring 20 nm (arrow), often broken and crossing meshes measuring 650 nm (f) [15]. 
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1.1.3 Mucus rheology 
 
Mucus is characterized as rheological reversible gel and has the rheological potential of 
conversion from gelled form to liquid form or vice versa .This reversibility property of mucus 
is due to its mucin mesh and other constituents which are non-covalently cross-linked 
together [16]. And therefore, bonds have the abilities to break and reform. 
The rheological properties of mucus can change as a function of stress, time scale (rate) of 
shearing as well as length scale. Changes in rheological properties of mucus may alter its 
ability to function as a lubricant, exchange nutrients, and its barrier properties against 
environmental threats (e.g. invasive pathogens) [5, 8]. 
Rheological measurements, including viscosity (resistance to flow) and elasticity (stiffness), 
are important behavior of all mucus secretions and all secretions broadly conform to the same 
pattern. However, the absolute moduli and flow stress values vary significantly depending on 
the source of mucus and physiological or pathological statues of the specimen [16, 17]. 
For instance, mucus blanket becomes too thick in cystic fibrosis patients where the sputum 
viscosity can be more than 100,000 times that of water, patients experiences difficulties to 
breathe due to reduction on mucus clearance capacity and bacterial overgrowth. The bulk 
rheology of mucus is non-Newtonian that is not linear with shear rate. Mucus has a strong 
resistance to deformation at low shear rates and weak resistance at high shear rates. Thus, 
bulk rheology is critical for proper clearance and lubrication function of mucus secretion 
[16]. 
The abnormal mucus secretion with altered rheology properties can result in morbidity and 
mortality in chronic airways diseases (e.g. asthma, cystic fibrosis (CF), and chronic 
obstructive pulmonary disease (COPD) Thus, normal mucus secretion is vital for 
maintenance human health [1, 10]. 
The shear-thinning (non-Newtonian) property of mucus gel is shown in Figure 1.7 by plotting 
the viscosity of mucus gel as a function of shear rate. As can be seen in the log-log plot, the 
viscosity of a mucus gel decrease as shear rate increases, whereas, the viscosity of water (a 
Newtonian fluid) does not change with shear rate as shown by the horizontal line (Figure 1.7) 
[2]. 
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It is apparent from Figure 1.7, that mucus behaviour is dependent on shear rate and that 
presumably results in decreasing adhesive interaction between mucus components (e.g. 
fibers) as the shear rate increases. At maximum physiological shear rate the viscosity of 
mucus gel approaches that of water mucus and, making mucus gel an excellent viscous 
lubricant [2]. 
                                                  
Figure 1.7: Summary of mucus viscosity as a function of shear rate for mucus obtained from 
many sources and observed by various methods.  
Note that viscosity decreases markedly as the shear rate increases (shear thinning), that most 
mucus secretions are rather comparable, and that all approach the viscosity of water at 
maximum physiological shear rates [18].    
Unstirred layer 
 
The gel nature of mucus provides an unstirred layer at the mucosal surfaces. Mucus does this 
by being shear-thinning gel which capable to form a lubrication slippage field between 
sliding surfaces as indicated in Figure 1.8 [2]. 
As mucus begins to supply between two epithelial surfaces the adhesive interactions within 
mucus fibers reduces, promoting mucus fibers to drawn apart and to create a slippage plain. 
As that happen, the viscosity of mucus gel reduces dramatically between the surfaces and 
causing gel layers remain unstirred (Figure 1.8) [1, 2]. 
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In the GI tract, mucus has important lubricant function. Bilayer sloppy lubricant mucus 
protects the underlying firmer gel and hence unstirred layer. In addition to the GI tract, mucus 
gel maintains this bilayer (a cell-adherent layer and non-adherent, luminal sloppy layer) in the 
female tract which is essential for mucus to perform lubricant task (Figure 1.8). 
The formation of slippage plane during copulation, swallowing, or peristalsis stimulated can 
be controlled by excess in mucus secretion between the cell-associated, unstirred and the non-
adherent layers. This causes the viscosity remain low between slippage planes as long as 
mucus is secreted. Indeed, slippage plane protect unstirred layer from breakage (Figure 1.8). 
Therefore, any object that needs to penetrate mucus must go up stream through mucus [18]. 
 
                           
                      Figure 1.8 Mucus as a lubricant gel on epithelial surface.  
Shearing action between two surfaces forms a slippage plane due to the non-Newtonian, 
shear-thinning property of mucus. Note each surface remains coated by an unstirred adherent 
layer of mucus [18]. 
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1.1.4 Mucus dynamics 
 
The dynamic viscoelastic properties of mucus secretions are integral to their physical 
function, in order to protect mucosal surfaces, maintain shear stress dependent lubrication, 
and to move over lung epithelial by mucociliary transport systems [17]. 
Mucus is continuously secreted and recycled to prevent pathogens or ultra-fine particulates 
from reaching the epithelial cells. Mucus lifetime is short from minutes to hours. Mucus 
turnover rate depends on its epithelial surface and the fastest mucus turn over being observed 
in thinnest mucus layer. Mucus facilitates the removal of particles in a matter of minutes to 
hours by its turnover, and can be replaced with new layer with approximately twenty minutes. 
Thus, this bio-gel is not only critical for human health maintenance, but it also significantly 
limits the potential for localized and sustained drug and gene delivery to mucosal surfaces 
(Figure 1.9) [1, 19]. 
Mucus turnover results in removal of toxic and foreign substance. Thus, pathogens and 
therapeutic nanoparticles must be able to diffuse upstream through mucus to reach underlying 
epithelium [18]. 
 
                                                                
               Figure 1.9: Dynamic properties of mucus (Taken from Nordgård). 
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1.1.5 Mucus barrier  
 
Mucosal tissues are preferential for therapeutic pharmaceutics administration, due to 
accessibility to targeted sites (e.g. GI and respiratory tracts) and minimum patient 
compliance. However, mucus presents a critical barrier for nanoscale drug delivery systems 
such as liposomes, polypeptides, and gene delivery, [8, 20]. 
1.1.5.2 Mucus barrier to pathogens in gut epithelium 
 
Mucus lines the gut epithelium with thick gel layer and that is considered as a major 
protective barrier for pathogenic bacteria and particles. However, pathogenic bacteria 
employed mechanisms to pass this mucus barrier and reach the epithelial surface (Figure 
1.10) [4]. 
In addition, epithelial and paneth cells themself secrete antimicrobial peptides to prevent 
bacterial penetration into the inner mucus layer. Thus, mucus layer function  as protective 
layer against bacterial colonization, in order to maintain a sterile environment over epithelial 
surfaces (Figure 1.10) [4]. 
Effective prophylactic and therapeutic based treatment could be possible by enhancing 
transport of medicine through mucus mesh without modifying its protective properties. This 
can be used for treating diseases such as cystic fibrosis (CF), sexually transmitted infections 
(STI), degenerative eye diseases, lung cancer, and irritable bowel disease [21]. 
                                        
                Figure 1.10: The mucus layer as barrier to pathogens in the gut [4]. 
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1.1.5.1 Mucus epithelial barrier to nanoparticle diffusion 
 
Mucus components can potentially stick to nanoparticle surfaces and may result in 
aggregation, destabilization, charge neutralization, and displacement of their cargoes to the 
unstirred layer discussed previously. In addition, mucus gel can limit free nanoparticle 
mobility by its adhesiveness. Therefore, nanoparticles do not freely diffuse in mucus and that 
is known as hindered nanoparticle motion. Mucus gel forms adhesive interactions with 
particulates upon their attachment via hydrophobic, electrostatic, and hydrogen bonding 
interactions (Figure 1.11) [1].  
In contrast, steric barrier depends on particle size, and that limits particle diffusion in the 
mucus. Wang et al. have studied the influence of particle size in mucus and have found that, 
particles with 1µm size or larger are significantly hindered in the mucus, whereas particle 
with smaller size for example 500nm able to diffuse in the mucus mesh in the absence of 
adherent interactions (Figure 1.11) [3]. 
Hydrophobic, electrostatic, and hydrogen bond are forms of attraction that are present in 
mucus and can overlap particles. A dense porous structure is formed by mucus gel. 
Therefore, nanoparticle must have small neural surfaces to avoid adhesion, in order to cross 
barrier [21]. 
                                                            
                             Interactive barrier                           Steric barrier 
                  Figure 1.11 : Mucus barrier components (Taken form Nordgård). 
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Nevertheless, mucus layers contain a large number of pores and low-viscosity channels that 
can allow nanoparticle to penetrate into underlying tissues.  
Electrostatic interactions mainly arise from the presence of carboxyl or sulfate groups on 
mucin- sugar bonds, and the strength of the electrostatic interactions and thus filtrating 
mechanism is regulated by both mucin charge states and particle surface chemistry [8]. 
Hydrophobic interactions arise from highly density of hydrophobic protein residues belong to 
mucin fibers, which creates various low-affinity adhesive interactions with hydrophobic 
surface of nanoparticle, result in immobilization of nanoparticle in mucus network [8]. 
Interactive and steric barriers can also be referred to interaction filtering and size filtering 
mechanisms which recently described by Siguerdsson and et al [7]. 
Size filtering mechanism allows nanoparticles that are smaller than mucus mesh’s pores to 
pass, whereas larger nanoparticles are rejected regardless of surface charge (green 
nanoparticles) (Figure 1.12 (a)) 
In contrast, Electrostatic, and/or hydrophobic forces and/or hydrogen bonds or specific 
banding interaction are involved in interaction filtering mechanism to prevent nanoparticles 
from crossing the mucus elements. Thus, surface chemistry of nanoparticle is a key player in 
this mechanism to enhance or to prevent particle diffusion in mucus blanket (orange 
nanoparticles) (Figure 1.12 (b)) [7]. 
                
Figure 1.12: Two main mechanisms employed to prevent nanoparticle diffusion in mucus 
gel. (a) Size filtering mechanism and (b) Interaction filtering [7]. 
Therefore, the effective transport of nanoparticles through mucus layer required to consider 
the barrier properties of mucus critically, in order to improve nanoparticle transport through 
mucus matrix, and to achieve desired therapeutic and diagnosis goals [8]. 
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1.2 Nanoparticle 
 
Nanoparticles can be defined as ultra fine particle with size ranges between 1 nm to 500 nm 
in at least two dimensions.  Nanoparticles have a wide potential usage in the area of, 
engineering, food industry, cosmetics and medicine. For instance, nanoparticles are used for 
drug delivery purposes due to their size and compatibility in biological environment [22].  
Synthetic nanoparticles typically feature hydrophobic, charged or hydrogen bonding surfaces, 
and these make them able to interact with mucus as biological environment. For example, 
Polystyrene nanoparticles are widely used as a model to study interactions between NPs and 
biological environments like mucus matrix, cells due to various practical reasons including 
their commercial availability, high quality and wide variety of size and surface chemistry  
Nanoparticles also can be used as sophisticated probe to discover the barrier properties of 
mucus surface to improve epithelial uptake of therapeutic agents [3, 22]. 
1.3 Nanomedicine and its application in penetrating of drug and gene delivery to mucus 
 
Nanomedicine is broad combination of multiple fields including, nanotechnology, 
biomolecular engineering, biology and medicine. Nanomedicine provides novel strategies in 
treatment of diseases, and overcome challenges faced by conventional therapies [23]. 
Nanotechnology provides new design of diagnostics or therapeutics on the nanoscale with 
many potential applications in clinical medicine and research. Due to their unique size 
dependent properties nanomaterial such as nanoparticles offer the possibility to navigate 
within the biological environment for the treatment, and prevention of disease. 
Thus, nanomedicine can be considered as applied-nanotechnology to medical problems. 
Nanomedicine approaches offer many applications in diagnosis and treatment of disease such 
as; nanoparticle-based molecular imaging probes for biological studies, nano-carriers for 
targeted drug and gene delivery, and regenerative medicine [24]. 
For example, in regard of drug delivery, nanomedicine tools have great potential to manage 
drug pharmacokinetics, non-specific toxicity, and immunogenicity for improved efficiency 
[24]. 
Delivery of genetic material and medicines via nanoparticle system may be a good strategy to 
combat a variety of disease affecting epithelial surfaces, including genetic disorders like 
cystic fibrosis, infectious diseases and cancers [21]. 
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Medical nanoparticles with the same size as biological entities can also interact in biological 
barriers like mucus. Therefore, understanding mucosal barriers and their interaction with 
foreign fine particles, can result in design of nanoparticles that are able to overcome this 
barrier and deliver its therapeutic agents into the targeted cells or tissue [23-25]. 
The resulting progress should open the way to more innovative and powerful in vivo 
diagnosis tools and treatment. 
 
In systematic drug delivery, drug transfers with either oral intake or intravenous injection 
which results in medicine distribution throughout the body regardless of specific binding to 
target site, whereas, in targeted nano-drug delivery, nanomedicine can localize and banded to 
desire targeted site in the body [26]. 
Thus , targeted drug delivery strategy (nano-drug delivery) can potentially reduce side effects 
of medicine due to a low drug dose, and more efficient way to administrate drugs as well as 
less costly (Figure 1.13) [26]. 
 
 
                                
 
Figure 1.13: Schematic presentation of systematic drug delivery versus targeted drug 
delivery through human body [27]. 
. 
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1.3 Alginate and G-blocks 
 
Alginate is a natural occurring family of polysaccharides produced by marine brown algae 
and bacteria, consisting of (1 → 4) linked β-D-mannuronic acid (M) and α-l-guluronic acid 
(G) residues. Alginate polymer is arranged by homopolymeric regions of M residue, G 
residue and alternating MG residue (mixture sequence) in blockwise patterns (Figure 1.14) 
[28, 29].  
The alginate polymer is commonly used in food industry due to gel forming ability, as well as 
viscosifying and stabilizing properties. Indeed, the application of alginate polymer within 
biotechnology and medicine can provide a novel pharmaceutical delivery to the target sites in 
the body. In addition, alginate polymer can form a hydrogel with multivalent cations (e.g. 
Ca
2+
) due to electrolyte nature and its physical properties [28]. 
 
                    
Figure 1.14: The schematic structure of alginate: a) Alginate monomer, b) Chain 
conformation, c) Block distribution [28]. 
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1.4.1 G-blocks ability to form a bio-gel in the presence of calcium  
  
Alginate biopolymer can produces three dimensional (3D) hydrogel structure in solution 
contains divalent Ca
2+
 due to form a bind with ionic interaction between G-blocks and 
cations. The 3D gel structure is known as “egg-box model” and shown in Figure 1.15 [29].  
G-blocks polysaccharide is negatively charged due to present of functional groups including 
oxygen, carboxylate oxygen as well as hydroxyl oxygen. There negatively charges residues 
over contribute to chelating aqueous cations such as Ca
+2
 and Mg
+2
. As shown in Figure 1.15- 
a and b, Ca
+2
 trapped inside and formed the junction zone with alginate polymer [30]. 
The ability of alginate to form a bio-gel is a key factor for its biological function and its 
application for drug delivery system. The G-blocks used in this study are extracted from high 
G alginate by acid hydrolysis preparation, and have an average DP of around 10. 
 
 
                                                                                    
Figure 1.15: Gel formation between G-blocks and calcium (Ca
2+) based on “egg box 
model”[31]. 
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1.5 Cystic fibrosis 
 
Cystic fibrosis (CF) is a monogenetic (Mutation on one gene) disorder, is caused by mutation 
on CFTR gene (Cystic fibrosis transmembrane regulator). This gene is responsible for 
chloride channel, and defective gene resulted in abnormally thick, sticky mucus that affects 
the lungs, the digestive system and respiratory system. There are complications in multiple 
organs but most significantly in lung and pancreas (Figure 1.16) [32]. 
As mucus becomes too thick, patients face great difficulty in mucus clearance, resulting in 
bacterial overgrowth. It also causes breathing problems, by clogging lung air ways. In 
addition, patient faces chronic infection specifically by bacterium named pseudomonas 
aeruginosa which secretes alginate, leading to declining lung function and ultimately 
respiratory failure [32].  
Cystic fibrosis is associated with considerable disability and early death, even though there 
have been improvements in patient’s survival and health situation in last two decades. 
Various medications comprehensive care plans, results in life expectancy life of 40 years for 
patients with cystic fibrosis [32]. 
Figure 1.16 shows a summary of the pathophysiology in the lung. Physiological changes of 
reduced CFTR activity in the lungs of patients with cystic fibrosis are highlighted by large 
gray arrows. Therapeutic classes that have been investigated for treatment of cystic fibrosis 
are shown in light gray boxes [32]. 
                     
                Figure 1.16: Strategy targets of cystic fibrosis respiratory therapies [32]. 
     Mucus barrier components, challenges for nanoscale drug delivery 
20 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
1.5.1 G-blocks in cystic fibrosis 
 
CF patients suffer from secretion of thick gelid mucus layer in their lung. The normal mucus 
removal system is unable to clear the mucus, resulting in mucus build and to respiratory 
failure. G-blocks are able to modify CF mucus and make it more mobile [17]. 
Nordgård and Draget have showed that, applying G-block into the CF mucus reduces mucus 
resistance to deformation (Figure 1.17) [17]. 
 
 
 
                  
                       
     Figure 1.17: Rheological disruption of CF sputum in the presence of G-blocks [17]. 
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1.6 G-block and enabling technology for nanomedicine applications 
 
It has been shown that G-blocks alter the mucin matrix architecture (personal 
communications with Nordgård/Draget) [17]. 
As shown in Figure 1.18 B G-blocks increased pore size of mucus mesh into more open 
network to diffuse in. These changes raise the possibility that G-blocks also alter mucus 
barrier properties. 
  
       
                                                                
Figure 1.18: Mucus network alteration with G-blocks treatment (A) Mucus matrix without 
G-blocks treatment, (B) mucus matrix after G-blocks treatment (Unpublished work from 
Draget and Taylor). 
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1.7 Multiple Particle Tracking  
 
Multiple particles tracking (MPT) is a powerful method for tracking the motion pattern of 
single particles. This method takes advantage of fluorescence video microscopy to detect and 
track the movements of individual fluorescence particles in a matrix (for example mucus). 
Referring to the diagram, the movements of particle in the matrix (in our case mucus) are 
observed through a confocal microscope and captured frame-wise as a film. The film is 
analyzed using the Image J plugin software, which selectively tracks single particles and 
relays each particle’s x and y position. Using Matlab predefined script gives mean square 
displacement (MSD) parameter and effective diffusivities (Deff) (MSD/4*T) further. 
Graphical representation of the obtained data can then be made by plotting the MSD and Deff 
values against time scale using the Sigma Plot software  (Figure 1.19) [20]. 
 
                                                                                                                     
                                                                                                   
                                              
                                                             
                                                                                                 
 
                  Figure 1.19: multiple particle tracking technique by procedure [20]. 
  
Real-time imaging Mucus samples in 
glass slide chamber 
Particle tracking by 
Image J plugin software 
Trajectory analysis Transport parameter 
calculation 
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1.7.2 Mean square displacement analysis 
 
A single trajectory of the each nanoparticle has x and y positional data over time. The 
obtained 2-dimentional position (x, y) can be used to calculate the mean square displacement 
(MSD) or (    ( )  ) over time scale and is given as [1]: 
     ( )                 (1) 
In this equation,   is time scale or time lag,        (    )   ( )  , and       
  (    )   ( )   (t indicates time in seconds) [33, 34].  
1.7.2.1 Time scale 
 
Assume a camera is able to capture 30 frames of images from a 20 second long movie. In 
total, there will be 600 recorded frames of particle. The time interval between each frame is 
33 ms, meaning that particle mobility can be calculated only frame-wise giving the shortest 
time scale of 33-ms (Figure 1.20) [35]. 
In this case, the 600 framed movies results in 599 displacement values. The next shortest time 
scale is 66ms which gives 598 displacement values. Thus, time scale can be defined as the 
time a particle is allowed to move around before its displacement value is determined based 
on the distance travelled from an initial point (Figure 1.20) [35]. 
 
                      
Figure 1.20: Illustration of time scale for 30 frame wise images obtained from a movie over 
20 second [35]. 
 
 
     Mucus barrier components, challenges for nanoscale drug delivery 
24 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
The mode of transport of each individual particle can be identified by the slop of the MSD 
versus time on a log-log scale. Three theoretical MSD plots based on differences in particle 
diffusivity are given in Figure 1.20. Each line represents the MSD of an individual particle 
which can be found by ascertaining mean the change in x and y position over time scale. 
Particle selection takes place randomly and analysis is done using the Image J plugin 
software. If a particle’s x and y position does not change over time scale the particle is 
classified as being immobile (Figure 1.21 A, red line), while limited changes in x and y 
position (particle mobility) over time scale is known as a sub-diffusive particle (Figure 1.21 
B, blue line). On the other hand, if the particle show significant changes in x and y position 
over time scale it is known as a mobile particle (Figure 1.21 C, green line) (Note that the 
number of tracked particles result variations in particle trajectories, and therefore MSD plot) 
(Figure 1.21) [36]. 
 
 
                                              
                          
Figure 1.21: Transport mode categorization by MSD plots, (A) an immobile particle (red 
plot), (B) a sub-diffusive particle (blue plot), and (C) a mobile particle (green). 
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1.7.1 Nanoparticle trajectories classification 
 
The particle trajectory shows the pattern movement by the particle during the observation. 
The form of the trajectory can give some information about the barriers to motion that 
particle experiences. 
 
                                                                                                                 
              
                                    
            
Figure 1.22: Nanoparticle trajectories based on their transport mode in mucus matrix [22, 
35]. 
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1.7.3 Effective diffusivity analysis 
 
The effective diffusivity can be calculated by the given equation [2]: 
     
    ( ) 
  
 (2) 
If Deff plot decreases with time scale nanoparticle display sub-diffusive motion, If Deff plot 
was constant with time scale nanoparticle display diffusive motion, and if Deff plot increases 
with time scale nanoparticle display active motion. Immobile particle can be identified by 
qualitative observations along with mathematical criteria (Figure 1.23) [33, 35]. 
 
                                       
Figure 1.23: Transport mode categorization by MSD plots: Diffusive (□), sub diffusive (●), 
and active (▴) [35]. 
Therefore, plotting MSD and Deff values against time scale allows analysis of the mode of 
particle motion.  
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1.7.3.1 Diffusivities 
1.7.3.1.3 Macroscopic diffusion 
 
The barrier experienced by a particle depends on particle size relative to the mesh size or the 
matrix (Figure 1.24). 
                    
Figure 1.24: Three models of nanoparticle diffusion in biological environment: (A) 
microscopic, (B) mesoscopic, and (C) macroscopic [35]. 
Multiple particle tracking may be used to determine the bulk-fluid rheological properties of 
mucus. In order to estimate the fluid navigation properties, the size of particle should be 
larger than the fluid pore sizes (Figure1 .24, part C). 
1.7.3.1.1 Microscopic diffusion  
 
In complex biological fluids like mucus, the measured fluid viscosity varies with length scale, 
due to the inhomogeneous nature of the mucus. The cause of the observed heterogeneities 
within the mucus gel can be attributed to microdomains or pores with lower viscosity fluid 
(Figure 1.24 A) [35].  
Multiple particle tracking can be used to identify the viscosity in these microdomains, where 
non-adhesive and small particles move freely in the interstitial fluid. By using the Stokes-
instein equation it is possible to calculate the microviscosity experienced by each particle. 
This equation is based on particle movement by simple diffusion, meaning that MSD data can 
be used to calculate the microscopic diffusion at early time scales when particles are under 
short range Brownian motion [37]. 
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1.7.3.1.2 Mesoscopic diffusion 
 
The size of particle determines its interactions in a complex biological environment. Particle 
mobility can be influenced by the dynamic of the fluid microstructure, for instance if the 
particle has the same size as the fluid pores in the biological environment. In this case, 
particles may show to be hindered at early time scale. However, alteration in the 
microstructure of the fluid contributes to particle diffusion which often displays biphasic 
behavior. This behavior can be seen as a decrease in Deff value with time at short time scales. 
This behavior can be seen as a decrease in Deff value with time at short time scales and 
reaches a constant value at long time scales. This constant lower value corresponds to the 
mesoscopic diffusion coefficient. The viscosity measured from the mesoscopic diffusivity 
would be lower than values provided by other conventional rheological techniques, due to 
particle accession to pores with lower viscosity. Therefore, particles have more free motion 
and using the particle tracking technique gives information about pore sizes in the mucus 
(Figure 1.24 A) [37].  
1.7.4 Beads on string 
 
Analysis of particle mobility does not necessarily explain the molecular origin of the barriers 
to movement. As shown in figure W, nanoparticle could be trapped in mucus mesh pores and 
being impeded or nanoparticle could be associated with  mucus fibers and such a non- 
statistic vibration mucus networks and both could result in similar trajectories (beads on a 
string) one of steric(A) and one of interactive origin (B) (Figure 1.25). 
                     
Figure 1.25: Mucus matrix as barrier to nanoparticle transport. Nanoparticle movement 
limited by both mucus mesh pores (A) and mucus network (B). 
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Chapter 2 
Material and methods 
2.1 Nanoparticles  
 
Carboxylate modified microspheres and amine modified microspheres were obtained from 
Invitrogen. These particles have yellow-green fluorescent color with 200 nm in diameter, and 
are mixed in distil water together with 2mM azide (2 % solides).   
The carboxylate modified microsphere products (product code: F8811) were made by 
grafting polymers with functional groups like carboxylic to sulfate chain of microspheres, 
giving both negative and hydrophilic surface to beads. Amine modified microsphere products 
(product code: F8764) were prepared by chemical modification hydrophilic with amine 
groups which gives positive charged beads. The amine and carboxylate nanoparticles are 
firmly hydrophobic, because they created by polystyrene materials. They greatly excited by 
setting the argon laser at 488 nm spectral line, results in intense fluorescence color. 
2.2 Porcine gastric mucin 
 
Gastric mucin extracted from porcine stomach was purchased from Sigma-Aldrich Norway 
AS, tevlingn 23, N-1081 Oslo (Product number: M2378), and was used for experiments in 
this master thesis. 
Porcine gastric mucin is similar to mucus which found in human, and therefore is a good 
model for studying nanoparticle mobility in mucus.  
2.3 Polymeric mucin 
 
Polymeric mucin was obtained from J.P. Pearson University of Newcastle, UK prepared 
according to the method of F.J.J Fogg et al [38]. 
Solubilized glycoprotein was purified in a CsCl density gradient (starting density 1.42 g·ml
-1
) 
and fractionated by Sepharose CL-2B column chromatography. The void volume fractions 
were pooled, dialysed, freeze-dried and used as polymeric mucin. Purity of mucin was 
determined by SDS/PAGE and staining with silver. Purified mucin was digested with papain 
(0.08 mg of papain/mg of glycoprotein, at 60 °C), for 48 h in 0.067 M sodium phosphate 
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buffer, pH 6.25, containing 5 mM cysteine hydrochloride and 5 mM EDTA. Digested mucin 
was fractionated in a further CsCl gradient, starting density 1.42 g·ml
-1
. Polymeric mucin was 
reduced with 0.2 M mercaptoethanol, for 24 h, at room temperature in 0.2 M Tris/HCl buffer, 
pH 8.0, containing 0.01 M EDTA, and was subsequently blocked overnight with 0.22 M 
iodoacetamide. Reduced mucin was fractionated in a further CsCl gradient, starting density 
1.42 g·ml
-1
 [38]. 
2.4 G-blocks dried powder  
 
G-blocks dried powder prepared according to the described method by Jørgensen et al [30]. 
The chemical composition, fraction of diad sequences FGG, FMG, and FMM, determined by 
high-field 
1H NMR, and intrinsic viscosity, [η], in 0.1 M NaCl at T = 20 °C determined in a 
capillary viscometer are summarized in Table 1. Low molecular weight G block alginates 
were produced by means of acid hydrolysis as previously described. 
2.5 MES sodium salt 
 
MES sodium salt was purchased from Sigma-Aldrich Norway AS, tevlingn 23, N-1081 
(product code M3885). MES sodium salt has molecular weight of 195.2 Da and chemical 
formulae of C6H12NNaO4S. In this experiment MES buffer at pH=6 was used as solvent in 
beads and mucus networks (see the supporting information in appendix). Mucus pH is 
depends on mucosal surfaces and pH range on mucosal surfaces is from the acidic pH in the 
gut and close to neutral pH in the lung. Therefore the optimal pH of MES buffer was selected 
for this experiment. 
2.6 Cover glass slide chamber 
 
The chambered cover glass (8 chamber-units, sterile) was purchase form Thermo Fisher 
Scientific, 75 Panorama creek D.r Rochester, NY 14625 USA. The chambered cover glass is 
intended to for cell culture applications employing high magnification inverted microscopes. 
The cover glass allows the microscope objective as close as possible to growing cells. In this 
master thesis, chambered cover glass was used for investigating nanoparticle motion in 
mucus samples. 
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2.7 Phase 1 of experiments 
2.7.1 Preparation of mucus matrixes 
 
Sigma pig mucus was prepared by dissolving sigma pig mucin (45 mg/ml) in MES buffer 
(100mM) at pH 6. Mucus was added to buffer and stirred gently overnight at 4ºC. 
Chambers were filled with 200 microliter sigma pig mucus (45 mg/ml), and 5 microliter of a 
mixture of particle-MES buffer stirred gently in 45 mg/ml of sigma pig mucus (a mixture: 10 
microliter of nanoparticle suspensions (2% w/w) was mixed with 40 microliter of MES buffer 
(100mM). 
2.7.2 Nanoparticle treatment with G-blocks to apply in mucus 
 
Ten microliter of nanoparticle suspensions (2% w/w) was mixed with 40 microliter of 
solubilized G-blocks (mg/ml) with MES buffer (100 mM) at pH 6. 5 microliter of this 
mixture was stirred gently in 200 microliter sigma pig mucus (45 mg/ml).  
2.7.3 Preparation of mucus matrixes 
 
A mixture of sigma pig mucus plus polymeric mucus was prepared by dissolving sigma pig 
mucin + polymeric mucin (30 mg/ml + 15 mg/ml) in MES buffer (100mM) at pH 6. Mucus 
was added to buffer and stirred gently overnight at 4ºC. 
Chambers were filled with 200 microliter of the mixture of sigma pig mucus plus polymeric 
mucin (30 mg/ml + 15 mg/ml), and 5 microliter of a mixture of particle-MES buffer stirred 
gently in mucus samples (10 microliter of nanoparticle suspensions (2% w/w) was mixed 
with 40 microliter of MES buffer (100mM). 
2.7.4 Nanoparticle treatment with G-blocks to apply in mucus 
 
Ten microliter of nanoparticle suspensions (2% w/w) was mixed with 40 microliter of 
solubilized G-blocks (mg/ml) with MES buffer (100 mM) at pH 6. 5 microliter of this 
mixture was stirred gently in 200 microliter of the mixture of sigma pig mucus plus 
polymeric mucus (30 mg/ml + 15 mg/ml).  
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* Mucus samples were sealed with parafilm to prevent of dehydration and left overnight for 
24 hours in a cold room (◦4C). Chambers were observed and were imaged at room 
temperature using a Leica microscope (TCS SP5).   
* Stirring: the suspensions were mixed in mucus samples. 
*Without stirring: the suspensions were added on top of 200 microliter mucus in chambers. 
2.8 Phase 2 of experiments 
2.8.1 Sample preparation 
 
Sigma pig mucus was prepared by dissolving sigma pig mucin (45 mg/ml) in MES buffer 
(100mM) plus 0.04 mg/ml G-blocks at pH 6. Mucus was added to buffer and stirred gently 
overnight at 4ºC. 
2.8.2 Mucus treatment with G-blocks 
 
Chambers were filled with 150 microliter sigma pig mucus (45 mg/ml) contains G-blocks 
(0.04 mg/ml) in 100mM MES buffer at pH 6. Then, 55 microliter of nanoparticle-MES buffer 
stirred gently in 150 microliter mucus (5 microliter of nanoparticle suspension + 50 microliter 
of MES buffer). 
2.8.3 Nanoparticle treatment with G-blocks 
 
Nanoparticles (5 microliter) mixed with 50 microliter of G-blocks solubilized in MES buffer 
(0.04 mg/ml G-blocks in 100 mM MES buffer) and 55 microliter of the mixture stirred gently 
in 150 microliter of sigma pig mucus (45 mg/ml) (Ten microliter of nanoparticle suspensions 
(2% w/w) was mixed with 50 microliter of solubilized G-blocks (0.04 mg/ml) in MES buffer 
(100 mM) at pH 6). 
2.8.4 Sample preparation 
 
Sigma pig mucus was prepared by dissolving sigma pig mucin (45 mg/ml) in MES buffer 
(100mM) plus 0.5 mg/ml G-blocks at pH 6. Mucus was added to buffer and stirred gently 
overnight at 4ºC. 
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2.8.5 Mucus treatment with G-blocks 
 
Chambers were filled with 150 microliter sigma pig mucus (45 mg/ml) contains G-blocks 
(0.5 mg/ml) in 100mM MES buffer at pH 6. Then, 55 microliter of nanoparticle-MES buffer 
stirred gently in 150 microliter mucus (5 microliter of nanoparticle suspension + 50 microliter 
of MES buffer). 
2.8.6 Nanoparticle treatment with G-blocks 
 
Nanoparticles (5 microliter) mixed with 50 microliter of G-blocks solubilized in MES buffer 
(0.5 mg/ml G-blocks in 100 mM MES buffer) and 55 microliter of the mixture stirred gently 
in 150 microliter of sigma pig mucus (45 mg/ml) (Ten microliter of nanoparticle suspensions 
(2% w/w) was mixed with 50 microliter of solubilized G-blocks (0.5 mg/ml) in MES buffer 
(100 mM) at pH 6). 
*All mucus samples were sealed to prevent of dehydration of mucus, and left overnight for 
24 hours in a cold room (◦4C). 
*The same procedure used to test the motion of both amine and carboxylate modified 
nanoparticles in sigma pig mucus. 
* Mucus samples were sealed with parafilm to prevent of dehydration and left overnight for 
24 hours in a cold room (◦4C). Chambers were observed and were imaged at room 
temperature using a Leica microscope (TCS SP5).   
2.9 Confocal Laser Scanning Microscopy 
 
Confocal Laser Scanning Microscopy is a powerful technique for observing sample 
molecules stained with fluorescent dyes. The fluorescent emission, resulting from excitation 
of electrons caused by an incident light, is focused onto a photo detector. Samples are 
scanned by laser in order to obtain high resolution optical images with depth selectivity. The 
confocal microscope was designed with the ability to acquire in-focus images from selected 
depths, which is known as optical sectioning. Images are acquired point-by-point and 
displayed at the appropriate spatial position on a TV monitor. This allows three-dimensional 
reconstructions of topologically complex objects [39]. 
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2.9.1 Sample visualization  
 
A Leica TCS SP5 laser scanning confocal microscope was used to capture images from 
mucus samples. Argon laser at 488 nm selected from laser setting to observe fluorescence 
dye. Laser excitation wavelength was set at 525nm and detection. A 63X 1.2/ water objective 
lens was used to obtain 512 frame wise images at 73 second time scales (image resolution 
512×512 pixels) (See Appendix C, Table C.1).  
2.10 Data analysis  
 
Obtained images from amine and carboxylate nanoparticles in mucus samples were process 
with Image J plugin software. The x and y position of 50 COOH nanoparticle trajectories 
were extracted with Image J plugin software and further using Matlab predefined script. The 
mean square displacement (MSD), and the averaged-mean square displacement (<MSD>) 
were calculated by provided values from Matlab software. The calculated MSD values 
allowed us to calculate the effective diffusivities (Deff) (MSD/4*T), and the average-mean 
effective diffusivities (<Deff>). 
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Chapter 3 
Results and Discussion 
3.1 The motion of carboxylate nanoparticles in sigma pig mucus 
 
To determine the motion of carboxylate-modified nanoparticles (200 nm in diameter) in 45 
mg/ml sigma pig mucus, experiments were performed in triplicate repeats for 50 COOH 
nanoparticles using multiple particle tracking (MPT). 
The following sample was studied, 
 Carboxylate nanoparticle suspensions were gently stirred in 45 mg/ml sigma pig 
mucus (stirred → nanoparticle suspensions were mixed in mucus). (Data analysis is 
provided in Figure 3.1). 
The x and y positional coordinates for carboxylate nanoparticle trajectories were imaged 
frame wise (512 frame obtained at 73-ms time scale), and were tracked by Image J plugin 
software. The analyzed two dimension (2D) particle motion was used to calculate the mean 
square displacement (MSD) value for the each carboxylate nanoparticle. 
Calculated MSD values allowed us to calculate the effective diffusivity (Deff) (MSD/4*T), 
the averaged-mean square displacement (<Deff>), as well as averaged-mean effective 
diffusivity (<Deff>) (note that all values were plotted as function of time scale) (Figure 3.1). 
Individual nanoparticle transport mode can be classified based on Deff plot in three modes; 
sub diffusive, diffusive, and active transport. If Deff plot decreases with time scale 
nanoparticle display sub-diffusive motion, If Deff plot was constant with time scale 
nanoparticle display diffusive motion, and if Deff plot increases with time scale nanoparticle 
display active motion. In addition, Deff plot lower than sub diffusive Deff plot over time 
scale can be classified as immobile. Immobile particles can be identified by MSD plot which 
show a constant trend with time scale.  Note that there should be no active motion in the 
mucus matrix, since there is no motor transport in mucus mesh [33, 35, 36]. 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
36 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
The first experiment investigated the motion of carboxylate modified nanoparticle in sigma 
pig mucus. Three replicate experiments were conducted at the same condition. 
There was a large variation in the individual particle trajectories and therefore MSD and Deff 
values which resulted in variability in the mean MSD and Deff values for 3 replicates. 
As can be seen from Figure 3.1, stirred COOH nanoparticles show that sub-diffusive mobility 
in 45 mg/ml sigma pig mucus, however there is a sub population of nanoparticles show 
diffusive motion with tendency to time scale.  
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Figure 3.1: The motion of carboxylate nanoparticle in sigma pig mucus.  (A, D, G) 
Triplicates ensemble mean square displacement (MSD), (B, E, H) effective diffusivity, (C, F, 
I) mean MSD (<MSD>) (solid line), and mean (<Deff>) (dashed line) for 50 carboxylate 
nanoparticles in 45 mg/ml sigma pig mucus (obtained between 0.1 to 10 seconds time scales). 
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Figure 3.2 provide triplicate mean MSD (<MSD>), and mean Deff (<Deff>) for 150 COOH-
modified polystyrene nanoparticles in 45 mg/ml sigma pig mucus by combing C, F, and I 
panels from the Figure 3.1. 
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Figure 3.2: Triplicate combined MSD and Deff in sigma pig mucus. Ensemble-averaged 
mean square displacement <MSD> (solid lines) and mean effective diffusivities <Deff> 
(dashed lines) of carboxylate-modified nanoparticles (200 nm in diameter) in 45 mg/ml sigma 
pig mucus provided by three replicate experiments between 0.1 to 10 second of time scales 
(Figure is combined plot of panels C, F, and I from Figure 3.1).  
 
In order to determine if results were representative, a set of exclusion criteria was applied 
over all triplicate results to determine if they could be considered as one data set.  
 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
38 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
3.2 Exclusion criteria 
 
Exclusion criteria are the standards to determine whether a group of data sets can be 
considered as a single set for data interpretation. The exclusion criteria can be different 
according to the research standards [40]. 
The applied exclusion criteria over triplicate results: 
Firstly any image series that showed apparent active transport was excluded. 
Basically nanoparticles would not show active transport in mucus network, because there is 
no motor active in there. Reasons for observation of nanoparticle with active movement could 
be due to sample drift in microscopic field of view or random thermal motion caused by 
microscope laser beam.  
Additionally, the flowing conditions must be satisfied for the replicates to be combined as a 
single data set. 
1. The members of all data set must show same mean MSD and Deff trends (sub diffusion, 
diffusion).  
2. All maximum MSD and Deff at 0.1 s to 10 s time scales must be above the all group mean 
MSD and mean Deff (represent by colored dots). 
4. All minimum MSD and Deff at 0.1 s to 10 s time scales must be below the all group mean 
MSD and mean Deff (represent by colored dots). 
We evaluated results of triplicate experiments and made the assumption if they resembled as 
same data set we can used them for data interpretation. Also, results of nanoparticles that 
showed active motion in mucus samples were excluded and did not considered further 
(nanoparticle with active transport display the effective diffusivity (Deff) increasing with 
time scale- Excluded results are presented in appendix A, Figures A.1, A.2, A.3, and A.4). 
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3.3 The comparison between triplicates maximum and minimum MSD and Deff values 
for carboxylate nanoparticles 
To quantify whether these three repeated mean MSD (<MSD>) and mean Deff (<Deff>) 
values can be treated as same data set, the maximum and minimum MSD and Deff values of 
50 stirred COOH-modified nanoparticles were compared for all group of results (triplicate 
experiments) and are shown in Figure 3.3 A , B. 
Considering point .1 all replicates means showed sub diffusive behavior (Figure 3.2). 
Considering point .2 all maximum MSD and Deff values at 0.1 s to 10 s time scales are above 
the all group mean MSD and mean Deff (represent by colored dots) (Figure 3.3 A and B). 
Considering point .3 all minimum MSD and Deff at 0.1 s to 10 s time scales are below the all 
group mean MSD and mean Deff (represent by colored dots) (Figure 3.3 A and B). 
Therefore these 3 replicates satisfy the above criteria and can be treated as a single data set. 
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Figure 3.3: Maximum and minimum MSD and Deff values of triplicate experiments for 
stirred carboxylate nanoparticles in sigma pig mucus. (A) Show maximum and minimum 
MSD values for 150 stirred carboxylate nanoparticles between 0.1 to 10 second times in 45 
mg/ml sigma pig mucus, and (B) Maximum and minimum Deffs values for 150 carboxylate-
modified nanoparticles between 0.1 to 10 second time scales in 45 mg/ml sigma pig mucus 
(Obtained from values in Figure 3.1). 
(B) (A) 
     Mucus barrier components, challenges for nanoscale drug delivery 
40 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
3.3.1 Discussion  
 
Results from triplicate experiments (MSD and Deff values) were considered as single data set 
for stirred carboxylate-modified nanoparticles in 45 mg/ml sigma pig mucus and is shown in 
Figure 3.4. As can be seen, carboxylate particles displayed sub diffusive motion. In general, a 
typical behavior of nanoparticles is to show sub diffusive motion in mucus matrix, which is in 
accordance with previous studies [13, 33]. 
Indeed, nanoparticles can exhibit diffusive, hindered, and immobile motion behavior in 
mucus matrix based on mucus barrier and the presence of biopolymer for example G-blocks 
[13, 41, 42]. 
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Figure 3.4: Graphical presentation of combined MSD and Deff values from triplicate results 
as a single data set. MSD plot (A) and Deff plot (B) in 45 mg/ml sigma pig mucus from 
triplicate experiments which considered as a single data set (Data analysis is shown in 
Chapter 3, Figure 3.1).  
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3.4 Study to investigate the effect of G-blocks on nanoparticle mobility in sigma pig 
mucus 
 
The motion of carboxylate-modified nanoparticles was investigated at 73-ms time interval in 
45 mg/ml sigma pig mucus using multiple particle tracking technique (MPT). 
The following samples were studied, 
1. Carboxylate nanoparticles were gently stirred into 45 mg/ml sigma pig mucus (stirred 
→ nanoparticles suspension mixed into the mucus). (Data analysis is provided in 
Chapter 3, Figure 3.1). 
2. Carboxylate nanoparticle suspensions mixed with 0.04 mg/ml G-blocks and were 
gently stirred into 45 mg/ml sigma pig mucus (stirred → nanoparticles treated with G-
blocks and the suspensions mixed into the mucus). (Data analysis is shown Chapter 5, 
Figure 5.4,). 
From 100-150 nanoparticle trajectories obtained in triplicate experiments, the mean square 
displacement (MSD) was calculated for each trajectory as well as averaged-mean square 
displacement (<MSD>). The same criteria for treating replicates as a single group was 
applied as describe in section 3.1.1 (Data analysis are presented in chapter 3, Figure 3.1 and 
in Chapter 5, Figure 5.4 respectively). 
To allow determination diffusive and sub diffusive particles, Deff values (MSD/4*T) were 
calculated and plotted as function of time scale. If Deff is constant with time scale, then 
particle shows diffusive motion. If Deff decreases with time scale, then particle shows sub-
diffusive mobility. 
We can see in Figure 3.5 B that, particles are sub-diffusive and <deff> values decreased with 
time scale. The <MSD> and <Deff> plots of carboxylate particles have similar shapes with 
and without of G-blocks (0.04 mg/ml).  
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Figure 3.5: The effect of G-blocks on stirred carboxylate nanoparticles motion in sigma pig 
mucus. Panel A and panel B show mean MSD <MSD> and mean Deff <Deff> values for 300 
stirred carboxylate nanoparticles with and without G-blocks (0.04 mg/ml) in 45 mg/ml of 
sigma pig mucus (obtained at 73-ms time intervals) (Data analysis are presented in chapter 3, 
Figure 3.1 and in chapter 5, Figure 5.4). 
3.4.1 Discussion  
 
Under these conditions G-blocks did not alter particle mobility. This may be because of the 
relatively degraded nature of sigma pig mucus. 
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3.5 Study to determine the influence of G-blocks on nanoparticle mobility in sigma pig 
mucus + polymeric mucus 
 
To determine if an increased content of non-degrade polymeric mucin altered the effect of G-
blocks, the motion of carboxylate nanoparticles was investigate in sigma pig mucus + 
polymeric mucus. Therefore, the following groups were studied, 
1. Carboxylate nanoparticles were gently stirred in 45 mg/ml sigma pig mucus + 
polymeric mucus (30 mg/ml + 15 mg/ml) without G-blocks treatment (stirred → 
nanoparticle suspensions were mixed into the mucus). (Data analysis is presented in 
Chapter 5, Figure 5.10).  
2. Carboxylate nanoparticles were treated with 0.04 mg/ml G-blocks, and were gently 
stirred in 45 mg/ml sigma pig mucus + polymeric mucus (30 mg/ml + 15 mg/ml) 
(nanoparticle suspensions were mixed into the mucus). (Data analysis is shown in 
Chapter 5, Figure 5.16).  
Considering the applied criteria, the analyzed mean <MSD> and mean <Deff> values show 
no different motion trend for particles treated with G-blocks and without G-blocks treatment, 
however, there is an indication that G-blocks may have led to more diffusive type motion at 
longer time scales. At time scales above 10s, treated particles with G-blocks were on average 
more mobile. 
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Figure 3.6: The effect of G-blocks on stirred carboxylate nanoparticles motion in sigma pig 
mucus + polymeric mucus. Panel A and panel B present mean MSD <MSD> and mean Deff 
<Deff> values for 100 stirred carboxylate nanoparticles with and without 0.04 mg/ml G-
blocks in 45 mg/ml of sigma pig mucus + polymeric mucus obtained at 73-ms time interval 
(Data analysis are presented in chapter 5, Figure 5.10 and Figure 5.16). 
3.5.1 Discussion  
 
Comparing Figure 3.5 and Figure 3.6, it can be seen no significant differences in the MSD 
and Deff values for nanoparticles with and without G-blocks in mucus matrix A or in mucus 
matrix B, however, a crossover was seen and that may indicate changes with G-blocks 
treatment that alter barrier at longer timescales. Therefore, further investigation is required. 
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3.6 Study to compare nanoparticle mobility in mucus types A and B 
 
In this study, multiple particle tracking was employed as previously described to investigate 
carboxylate nanoparticles motion in mucus matrix A (sigma pig mucus) and mucus matrix B 
(sigma pig mucus + polymeric mucus).  Therefore, the following samples were taken into 
account, 
1. Carboxylate nanoparticles were gently stirred in 45 mg/ml mucus matrix A (sigma pig 
mucus) (stirred → nanoparticle suspensions were mixed with into the mucus) (Data 
analysis is shown in Chapter 3, Figure 3.1) 
2. Carboxylate nanoparticles were gently stirred in 45 mg/ml mucus matrix B (sigma pig 
mucus + polymeric mucus) (30 mg/ml + 15 mg/ml) (stirred → nanoparticle 
suspensions were mixed with into the mucus) (Data analysis is presented in Chapter 5, 
Figure 5.10). 
The averaged-mean square displacement MSD (<MSD>) (a) and the averaged-mean effective 
diffusivity (<Deff>) were compared for carboxylate nanoparticles in Mucus A and Mucus B 
and are shown in Figure 3.7. As can be seen from Figure 3.7 a and b, <MSD> and <Deff > 
values are approximate 10 fold greater for mucus matrix B than mucus matrix A.  
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Figure 3.7: Carboxylate nanoparticles motion in mucus matrix A and matrix B. Panel a and b 
Provide mean MSD <MSD> and mean Deff <Deff> values for 100 stirred carboxylate 
particles in 45 mg/ml of mucus matrix A (sigma pig mucus) and mucus matrix B (sigma pig 
mucus + polymeric mucus) (Data analysis are presented in Chapter 3 Figure 3.1, and in 
chapter 5, Figure 5.10).  
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In addition, carboxylate particles appeared to be more diffusive in mucus matrix B (higher 
Deff plot). It was found that, carboxylate nanoparticles experienced less barrier to movement 
when polymeric mucus was added into the sigma pig mucus.  
3.6.1 Discussion  
 
The results of this study revealed the involvement of mucus components as movement barrier 
to nanoparticle motion, and existing challenges for nanoscale drug delivery. The degree of 
nanoparticle motion depends on the spacing between mucus fibers and its elements and the 
interactions with mucus components. Interestingly, carboxylate-modified nanoparticles 
diffused rapidly through mucus matrix B than mucus matrix A. 
One possible explanation would be that, polymeric mucus makes more pores or provides a 
scaffold in mucus network and that resulted in increased particle mobility.  
It also seems possible that, increased nanoparticle motion in matrix B is most likely due to 
different matrix architecture between sigma pig mucus and polymeric mucus (Figure 3.8). 
Thus, choosing a proper mucus matrix is critical for studying its behavior.  
 
 
                     
 
Figure 3.8: Schematic representation of mucus matrix A (sigma pig mucus) and mucus 
matrix B (sigma pig mucus + polymeric mucus). 
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3.7 Study to compare nanoparticle motion in mucus matrix A and mucus matrix B in 
the presence of G-blocks 
 
The same study was performed as section 3.6 to determine changes on carboxylate 
nanoparticles mobility in the presence of G-blocks in mucus matrix A (sigma pig mucus) and 
mucus matrix B (sigma pig mucus + polymeric mucus).  Therefore, the following samples 
were taken into account, 
Therefore, the following studies were investigated, 
1. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were gently stirred in 
45 mg/ml mucus matrix A (sigma pig mucus) (stirred → nanoparticle suspensions were 
mixed with into the mucus) (Data analysis is shown in Chapter 5, Figure 5.4) 
2. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were gently stirred in 
45 mg/ml mucus matrix B (sigma pig mucus + polymeric mucus) (30 mg/ml + 15 mg/ml) 
(stirred → nanoparticle suspensions were mixed with into the mucus) (Data analysis is 
presented in Chapter 5, Figure 5.16). 
Analyzed MSD and Deff values confirmed that carboxylate nanoparticles diffused greater in 
mucus matrix B than in mucus matrix A to an extent similar to study 3.6. 
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Figure 3.9: Carboxylate nano particles motion in the presence of G-blocks in mucus matrix 
A and matrix B. Panels c and d provide mean MSD <MSD> and mean Deff <Deff> values 
for 100 stirred carboxylate particles treated with G-blocks in 45 mg/ml of Mucus matrix A 
(sigma pig mucus) and Mucus matrix B (sigma pig mucus + polymeric mucus) (200 nm in 
diameter, obtained at 73-ms time intervals) (Data analysis are provided in chapter 5, Figure 
5.4 and in Figure 5.16).  
3.7.1 Discussion  
 
As evident from both Figures 3.7 and 3.9 increased carboxylate nanoparticles motion in 
mucus matrix B is not likely due to G-blocks treatment, but is due to the presence of 
polymeric mucus in mucus matrix B. 
The differences between the two matrices are similar with and without G-block treatment. In 
this case the matrix is the biggest determinant of particle mobility. Thus it is important to 
choose appropriate mucus matrix for investigation of nanoparticle motion. 
It has been shown that nanoparticle motion can be categorized directly on mucus matrix 
obtained from animals, reasoning that the unique rheological and barrier properties required 
at each mucosal surface give rise to different mesh spacinsgs or other structure properties, 
which has important implications for mucosal drug and gene delivery [43]. 
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3.8 Study to quantify the method of bead addition on nanoparticle mobility in sigma pig 
mucus 
 
To evaluate whether the method of nanoparticles (beads) addition makes difference to 
nanoparticle motion, the motion of stirred versus unstirred carboxylate-modified 
nanoparticles compared in 45 mg/ml sigma pig mucus by MPT. 
Therefore, the following examination were taken into account,  
1. Carboxylate nanoparticles were gently stirred into 45 mg/ml sigma pig mucus (Stirred 
→ nanoparticle suspensions were mixed in mucus samples). (Data analysis is 
presented in Chapter 3, Figure 3.1) 
2. Carboxylate nanoparticles were added into 45 mg/ml sigma pig mucus (Unstirred → 
nanoparticle suspensions were added on top in mucus samples in chamber). (Data 
analysis is shown in Chapter 5, Figure 5.1) 
3. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were gently stirred 
into 45 mg/ml sigma pig mucus (Stirred → nanoparticle suspensions were mixed in 
mucus samples). (Data analysis is provided in Chapter 5, Figure 5.4) 
4. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were added into 45 
mg/ml sigma pig mucus (Unstirred → nanoparticle suspensions + G-blocks were 
added on top in mucus samples in chamber). (Data analysis is shown in Chapter 5, 
Figure 5.7). 
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The mean square displacement (MSD) and effective diffusivity (Deff) were calculated for 
150 stirred versus unstirred carboxylate-modified nanoparticles treated with and without 0.04 
mg/ml G-blocks in 45 mg/ml sigma pig mucus (Figure 3.10). 
The mean MSD (<MSD>) (A, C) and mean Deff (<Deff>) (B, D) plots indicates differences 
but these are not large enough to be considered significant at these stage (considering the 
applied exclusion criteria) (Figure 3.10). 
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Figure 3.10: Study the method of beads addition on carboxylate particle mobility in sigma 
pig mucus. Panels A-C and B-D show mean MSD (<MSD>) and mean Deff (<Deff>) values 
for stirred versus unstirred particles for 150 carboxylate nanoparticle trajectories (200 nm in 
diameter, obtained at 73-ms time intervals) in 45 mg/ml sigma pig mucus (Data analysis are 
provided in Chapter 3, Figure 3.1, and in chapter 5, Figure 5.1, Figure 5.4 and Figure 5.7).  
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3.8.1 Study to verify the effect of bead addition on nanoparticle mobility in sigma pig 
mucus + polymeric mucus 
 
The same study as in section 3.8, Figure 3.10 was repeated using mucus matrix B (sigma pig 
mucus + polymeric mucus). To further understand whether the motion of stirred versus 
unstirred nanoparticles would differ based on mucus mesh network, the method of beads 
addition (stirred versus unstirred) was investigated in 45 sigma pig mucus + polymeric mucus 
(30 mg/ml + 15 mg/ml) using multiple particle tracking. 
Therefore, the following samples were taken into account, 
1. Carboxylate nanoparticles were gently stirred into 45 mg/ml sigma pig mucus + polymeric 
mucus (Stirred → nanoparticle suspensions were mixed in mucus samples). (Data analysis is 
presented in Chapter 3, Figure 3.1) 
2. Carboxylate nanoparticles added into 45 mg/ml sigma pig mucus + polymeric mucus 
(Unstirred → nanoparticle suspensions were added on top in mucus samples in chamber). 
(Data analysis is shown in Chapter 5, Figure 5.1) 
3. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were gently stirred into 
45 mg/ml sigma pig mucus + polymeric mucus (Stirred → nanoparticle suspensions were 
mixed in mucus samples). (Data analysis is provided in Chapter 5, Figure 5.4) 
4. Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were added into 45 
mg/ml sigma pig mucus + polymeric mucus (Unstirred → nanoparticle suspensions + G-
blocks were added on top in mucus samples in chamber). (Data analysis is shown in Chapter 
5, Figure 5.7). 
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Figure 3.11 compares the averaged mean square displacement (<MSD>) (A, C) and averaged 
effective diffusivity (<Deff>) (B, D) values for 150 stirred versus unstirred COOH 
nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus (30 mg/ml + 15 mg/ml). 
As can be seen from Figure 3.11, there are no differences between mean MSD (<MSD>) (A, 
C) and mean Deff (<Deff>) (B, D) plots for 150 stirred versus unstirred COOH nanoparticles 
over 73 second of time scales. Stirred nanoparticle versus unstirred nanoparticle showed 
similar <MSD> and <Deff> plots in the presence and in the absence of 0.04 mg/ml G-blocks. 
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Figure 3.11: Study the method of beads addition on carboxylate nanoparticle mobility in 
sigma pig mucus + polymeric mucus. Panels A-C and B-D present mean MSD (<MSD>) and 
mean Deff (<Deff>) values for stirred versus unstirred particles for 150 carboxylate 
nanoparticle trajectories with and without 0.04 mg/ml G-blocks treatment in 45 mg/ml 
polymeric mucus + sigma pig mucus (200 nm in diameter, obtained at 73-ms time intervals) 
(Data analysis are provided in Chapter 5, Figures 5.10, Figure 5.13, Figure 5.16 and Figure 
5.19). 
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3.8.2 Discussion  
 
Interestingly whilst the results for both matrix A and matrix B for stirred vs. unstirred could 
not be considered significant based on the exclusion criteria the means MSD plus Deff from 
matrix B were much more similar than those from matrix A. 
It can be reasoned that, similarity between MSD and Deff plot for carboxylate nanoparticles 
in mucus matrix B is due to ability of mucus matrix B to re-built its network much faster than 
mucus matrix A, and hence show the functional importance of mucus rheology. 
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3.9 Alteration mechanisms to mucus barrier function and enhancing uptake of 
therapeutic in drug delivery system 
As earlier pointed out, mucus glycoprotein is highly negatively charges and contains 
hydrophilic glycosylated protein domains. In the presence of charged nanoparticle (negative 
or positive surface charge) as well as G-blocks polymer, mucus mesh pores can be modified 
and promote nanoparticles to cross the mucosal barrier. 
G-blocks polymer can alter the mucus matrix through two mechanisms: 
 Coating the nanoparticles and mucus matrix with G-blocks alter the interaction 
between nanoparticle and mucus mesh 
 Alter matrix architecture (Figure 3.12). 
Referring to Figure 3.12, in the absence of G-blocks polymer nanoparticles were trapped in 
mucin fibers (A), coating nanoparticles with G-blocks polymer could decrease nanoparticle-
mucus interaction and caused nanoparticle to diffusive through mucus mesh (B), and treated 
mucus network with G-blocks could alter its architecture and nanoparticles could cross the 
mucus barrier and (C).        
                  
Figure 3.12: Schematic illustration of nanoparticles interaction in mucus network, A) 
nanoparticles interaction in mucus mesh without G-blocks treatment, B) treated nanoparticles 
with 0.04 mg/ml G-blocks and were stirred gently in mucus matrix, and C) nanoparticle 
motion in mucus matrix contained 0.04 mg/ml G-blocks (G-blocks shown in blue). 
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The previous studies considered situation (A), where particle were mixed with G-blocks 
before being added to the mucus. 
To study the effects of G-blocks on both mucus architecture and nanoparticle in more detail 
the collective study undertaken to consider; 
1. The effect of adding G-blocks to the mucus compared to adding G-blocks to the 
particles. 
2. Testing amine nanoparticle together with carboxylate nanoparticles which have 
positive and negative surface charges respectively is critical to see the effect of 
surface chemistry in mucus matrix. 
 In this study 1 matrix was chosen (45 mg/ml of sigma pig mucus), because this removes a 
potential variation of the two mucin types. 
Additionally, nanoparticle suspensions were stirred into the mucus, because the matrices 
were subjected to mixture with the addition of G-blocks (stirred → nanoparticle suspensions 
were mixed in mucus). 
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3.10 Transport of carboxylate-modified nanoparticles in sigma pig mucus mixed with 
G-blocks 
 
The transport of carboxylate-modified nanoparticles was investigated in mucus samples using 
multiple particle tracking technique (MPT). 
The following samples were studied, 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus without G-blocks 
treatment. (Data analysis is provided in Chapter 5, Figure 5.23, panels M, N, and O) 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.04 
mg/ml G-blocks. (Data analysis is provided in Chapter 5, Figure 5.22, panels A, B, 
and C) 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.5 
mg/ml G-blocks. (Data analysis is provided in Chapter 5, Figure 5.22, panels D, E, 
and F). 
For all three screens above (1, 2, and 3), nanoparticle suspensions were gently stirred in 
mucus samples (Stirred → nanoparticle suspensions were mixed in mucus samples). 
The mean MSD (<MSD>) values (A) and mean Deff (<Deff>) values (B) of 300 individual 
carboxylate-modified nanoparticles are presented in Figure 3.13. As can be seen from Figure 
3.13 there are differences between mean MSD and mean Deff plots for carboxylate 
nanoparticles in the presence of G-blocks in mucus compared with <MSD> and <Deff> plots 
control of carboxylate nanoparticles in mucus with no G-blocks (MSD and Deff plots).  
The <MSD> and <Deff> plots were greater for COOH nanoparticles in the presence of 0.04 
mg/ml G-blocks in mucus. In contrast, <MSD> and <Deff> plots displayed a trend toward 
less movement for COOH nanoparticles in 45 mg/ml sigma pig mucus treated with 0.5 mg/ml 
G-blocks (green plot versus red plot) (Figure 3.13). 
Interestingly, the differences between MSD and Deff plots were reduced at longer time scales 
for carboxylate nanoparticles in mucus sample treated with 0.5 mg/ml G-blocks and in mucus 
sample without G-blocks inside it (red and blue plots) (Figure 3.13). 
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Figure 3.13: Transport of carboxylate nanoparticle in sigma pig mucus contains G-blocks. 
Ensemble <MSD> (A) and <Deff> (B) values of 300 COOH-modified nanoparticles  in 45 
mg/ml sigma pig mucus with no G-blocks treatment, in 45 mg/ml sigma pig mucus treated 
with 0.04 mg/ml G-blocks, and in 45 mg/ml sigma pig mucus treated with 0.5 mg/ml G-
blocks obtained at 73-ms time interval (Figure 5.23, panels M, N, and O, Figure 5.22, panels 
A, B, and C, and Figure 5.22, panels D, E, and F). 
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3.10.1 Transport of carboxylate-modified nanoparticles treated with G-blocks in sigma 
pig mucus  
The transport of carboxylate-modified nanoparticles was investigated in 45 mg/ml sigma pig 
mucus using multiple particle tracking (MPT).  
The following samples were studied, 
 Carboxylate nanoparticle suspensions were gently stirred in 45 mg/ml sigma pig 
mucus (stirred → nanoparticle suspensions were mixed in mucus). (Data analysis is 
provided in Chapter 5, Figure 5.23, panels M, N, and O). 
 Carboxylate nanoparticle suspensions mixed with 0.04 mg/ml G-blocks and were 
stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions were 
mixed in mucus). (Data analysis is shown in Chapter 5, Figure 5.23, panels G, H, and 
I ) 
 Carboxylate nanoparticle suspensions mixed with 0.5 mg/ml G-blocks and were 
stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions 
mixed in mucus). (Data analysis is presented in Chapter 5, Figure 5.23, panels J, K, 
and L). 
The averaged-mean square displacement (<MSD>) values (a) and averaged-mean effective 
diffusivity (<Deff>) values (b) of 300 individual carboxylate-modified nanoparticles are 
shown in Figure 3.14. As can be seen from Figure 3.14, there are a slight differences between 
mean MSD and mean Deff plots for carboxylate nanoparticles treated with two G-blocks 
concentrations (0.04 and 0.5 mg/ml respectively) compared to carboxylate nanoparticles 
without G-blocks treatment in 45 mg/ml sigma pig mucus (red, blue, and green plots). 
It is apparent from Figure 3.14 <MSD> and <Deff> plots displayed greater motion for COOH 
nanoparticles treated with 0.5 mg/ml G-blocks than those for COOH nanoparticles with 0.04 
mg/ml G-blocks as well without G-blocks treatment (read plot versus green and blue plots) 
(Figure 3.14). 
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Figure 3.14: Transport of carboxylate nanoparticles treated with G-blocks in sigma pig 
mucus. Ensemble <MSD> (a) and <Deff> (b) values of 300 carboxylate-modified 
nanoparticles with no G-blocks treatment, treated with 0.04 mg/ml G-blocks, and treated with 
0.5 mg/ml G-blocks in 45 mg/ml sigma pig mucus obtained at 73-ms time interval (Data 
analysis are shown in Chapter 5, Figure 5.23, panels M, N, and O, Figure 5.23, panels G, H, 
and I, and Figure 5.23, panels J, K, and L). 
 
3.10.1.2 Discussion  
 
Comparing with section 3.10, Figure 3.13, it is somewhat surprising that the method of G-
blocks addition makes such a difference to the results because both G-blocks and 
nanoparticles are negatively charged so it is not expected that G-blocks would interact 
strongly with the nanoparticle, and therefore it might be assumed that order of mixing would 
not has a significant effect at this stage it is unclear why there differences are seen. 
Lai et al [41] reported that, polystyrene beads without PEGylated coating form polyvalent 
bonds with hydrophobic domain distributed along mucus fibers. In addition they found that, 
the rapid diffusion of PEGlyted nanoparticles is because of nanoparticles movement in low 
viscosity channels or pores within the mucus.  
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Benjamin S. Schuster [42] found that nanoparticles coated with PEG as large as 200 nm in 
diameter can diffuse faster in human respiratory mucus without lung diseases. They 
suggested that, PEG coating nanoparticle reduces particle adhesion to mucus matrix, and that 
lead to freely particle diffusion through mucus. The carboxylate particles showed sub 
diffusive motion which is similar with published studies [3,13, 41]. 
G-blocks altered particle mobility but it is not clear how. 
There are several possible explanations for these results. A possible explanation would be 
that G-blocks alter porous structure of mucus network to more favorable for nanoparticles to 
traverse in. The alteration might be due to formation of covalent bound between G-blocks 
polymer and mucus fibers, making a new mucus matrix rearrangement which is easier to pass 
through. 
Another possible explanation for this is that, the present of sodium salt (MES buffer) together 
with G-blocks, making mucus as electrolyte solution resulting in dissolution of mucus matrix 
and therefore, nanoparticle could penetrate in mucus network. 
It is not clear why a low concentration of G-blocks would negatively influence particle 
mobility based on these ideas. 
To investigate the effect of mixing order further amine nanoparticles were used. These 
particles have a positive surface charge and can be coated by G-blocks (negative charge). So 
the mixing order may be expected to alter the results.  
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3.11 Transport of amine-modified nanoparticles in sigma pig mucus mixed with G-
blocks 
 
To explore changes in the interaction between nanoparticles and mucus network in the 
presence of G-blocks, amine nanoparticles was used. 
The following samples were studied, 
 Amine nanoparticles were gently stirred in 45 mg/ml sigma pig mucus (Stirred → 
nanoparticle suspensions mixed in mucus sample) (Data analysis is provided in 
Chapter 5, Figure 5.25, panels B, C, and D) 
 Amine nanoparticles were gently stirred in 45 mg/ml sigma pig mucus mixed with 
0.04 mg/ml G-blocks (Stirred → nanoparticle suspensions mixed in mucus sample) 
(Data analysis is provided in Chapter 5, Figure 5.24, panels V, W, and X) 
 Amine nanoparticles were gently stirred in 45 mg/ml sigma pig mucus mixed with 0.5 
mg/ml G-blocks (Stirred → nanoparticle suspensions mixed in mucus sample) (Data 
analysis is provided in Chapter 5, Figure 5.24, panels Y, Z, and A). 
Figure 3.15 presents the results of the ensemble averaged-mean square displacement 
(<MSD>) (C) and averaged effective diffusivity (<Deff>) (D) values over 300 amine-
modified nanoparticles in 45 mg/ml sigma pig mucus.  
There was a significant difference between man MSD (<MSD>) and mean Deff (<Deff>) of 
amine nanoparticles in 45 mg/ml sigma pig mucus mixed with 0.5 mg/ml and 0.04 mg/ml of 
G-blocks respectively. 
Amine nanoparticles showed sub diffusive <MSD> and <Deff> plots in sigma pig mucus 
mixed with 0.04 mg/ml G-blocks and 0.5 mg/ml G-blocks respectively (Green and black 
plots) (Figure 3.15 D). 
Amine nanoparticles displayed greater Deff plot in sigma pig mucus without G-blocks 
treatment at short time scale, however, at longer time scale deff plot showed downward trend, 
and hence less motion of amine nanoparticles (blue plot) (Figure 3.15 D). 
A shift toward more diffusive motion acquired in mild time scales for amine nanoparticles in 
sigma pig mucus mixed with 0.04 mg/ml G-blocks(green plot) (Figure 3.15 D). 
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Figure 3.15: Transport of amine nanoparticle in sigma pig mucus contains G-blocks. 
Ensemble <MSD> (C) and <Deff> (D) values of 300 Amine-modified nanoparticles  in 45 
mg/ml sigma pig mucus with no G-blocks treatment, in 45 mg/ml sigma pig mucus treated 
with 0.04 mg/ml G-blocks, and in 45 mg/ml sigma pig mucus treated with 0.5 mg/ml G-
blocks obtained at 73-ms time interval (Data analysis are provided in Chapter 5, Figure 5.25, 
panels B, C, D, Figure 5.24, panels P, Q, and R, and Figure 5.24, panels S, T, and T). 
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3.11.1 Discussion  
 
Amine particles without G-blocks treatment showed MSD curve flattens out with increased 
time scale indicates that over a certain time scale nanoparticle are not moving further. Treated 
amine particles with lower concentration of G-blocks (0.04 mg/ml) exhibit a significant 
motion improvement at longer time scale. 
Treated amine particles with higher concentration of G-blocks (0.5 mg/ml) exhibit a slower 
trend toward motion improvement. Amine particles displayed sub diffusive mobility by 
treating with both G-blocks concentrations (0.04 and 0.5 mg/ml G-blocks). 
This finding lead to our hypothesis that, the amine nanoparticles were trapped in electrostatic 
interaction at short time scale, but the effect reduced at longer time scales due to the presence 
of G-blocks in mucus network, resulting in less hindered nanoparticles at longer time scales.  
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3.11.2 Transport of amine-modified nanoparticles treated with G-blocks in sigma pig 
mucus 
 
The motion of amine-modified nanoparticles treated with 0.04 and 0.5 mg/ml G-blocks were 
studied individually and compared to amine nanoparticles without G-blocks treatment in 45 
mg/ml sigma pig mucus 
Therefore, the following samples were studied, 
 Amine nanoparticle suspensions were gently stirred in 45 mg/ml sigma pig mucus 
(stirred → nanoparticle suspensions mixed in mucus) (Data analysis is provided in 
Chapter 5, Figure 5.25, panels B, C, and D). 
 Amine nanoparticle suspensions mixed with 0.04 mg/ml G-blocks and were stirred 
gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions mixed in 
mucus) (Data analysis is shown in Chapter 5, Figure 5.25, panels V, W, and X) 
 Amine nanoparticle suspensions mixed with 0.5 mg/ml G-blocks and were stirred 
gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions mixed in 
mucus) (Data analysis is presented in Chapter 5, Figure 5.25, panels Y, Z, and A). 
The analyzed averaged-mean square displacement <MSD> (c) and averaged-mean effective 
diffusivity <Deff> values (d) for 300 individual amine-modified nanoparticles are shown in 
Figure 3.16. 
Amine nanoparticles showed greater sub diffusive movement at short time scales and hence 
higher MSD and Deff plots, however, this trend motion decreased at longer time scales (blue 
plot) (Figure 3.16). 
Remarkably, treated amine nanoparticles with 0.04 mg/ml G-blocks results in a shift to bitter 
mobility at longer time scales as shown by MSD and Deff plots (green plot) (Figure 3.16 c 
and d). In contrast, treated amine nanoparticles with 0.5 mg/ml G-blocks exhibited the lowest 
MSD and Deff plots, and therefore less mobility (black plot) (Figure 3.16 c and d). 
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Figure 3.16: Transport of amine nanoparticles treated with G-blocks in sigma pig mucus. 
Ensemble <MSD> (c) and <Deff> (d) values of 300 amine-modified nanoparticles with no G-
blocks treatment, treated with 0.04 mg/ml G-blocks, and treated with 0.5 mg/ml G-blocks in 
45 mg/ml sigma pig mucus obtained at 73-ms time interval (This data analysis is presented in 
chapter 4 Figure 4.25, panels B, C, D, Figure 4.25, panels V, W, X, and Figure 4.25, panels 
B, C, D). 
3.11.3 Discussion  
 
Interestingly the mixing order did not alter the mobility of the particles to a large degree. 
However, the shift toward greater motion was observed at longer time scales (approximation 
10 second) for amine nanoparticles treated with 0.04 mg/ml G-blocks. 
Mucus treatment with G-blocks was more effective than nanoparticle treatment with G-
blocks in both studies on amine and carboxylate nanoparticles. 
This might indicate that G-blocks induced changes occur at a matrix level not a particle level. 
In both cases higher levels of G-blocks cause a significant decrease in particle motion. If G-
blocks alter the matrix it is possible that high levels of G-blocks collapse all the structure and 
increase the mucus barrier.  
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If the G-blocks are mixed directly into the mucus matrix they can alter mucus architecture. If 
the G-blocks are mixed first with the nanoparticle then they must compete more with 
nanoparticle to the mucus matrix before they can alter mucus architecture. 
Mucus barriers can be up to 450 µm for example in gastrointestinal tract or in respiratory 
tract with averaged size of 15 µm. Improvement in nanoparticle mobility at longer time scales 
(longer distances) could be relevant for drug delivery to engineer medical nanoparticles that 
can experience mucus barrier for a longer times, and hence release their pharmaceutics 
through mucus matrix.  
It can thus be suggested that, improvements in increasing nanoparticle motion can be 
achieved by G-blocks treatment. However, more research on this topic needs to be 
undertaken before identifying the mechanism implications of G-blocks in the mucus network. 
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3.12 The transport of amine nanoparticle vs. carboxylate nanoparticles in sigma pig 
mucus  
 
To compare the transport of amine particle vs. carboxylate particles in 45 mg/ml sigma pig 
mucus, the averaged-mean square displacement (<MSD>) and the averaged-mean square 
displacement (<Deff>) of amine versus carboxylate nanoparticles were plotted as function of 
time scale and are present in Figure 3.17 A and B respectively.  
Therefore, the following studies were taken into account, 
 Amine nanoparticle suspensions were gently stirred in 45 mg/ml sigma pig mucus 
without G-blocks treatment (Stirred → Nanoparticle suspensions were mixed into 
mucus samples). (Data analysis is presented in Chapter 5, Figure 5.25, panels B, C, 
and D). 
 Carboxylate sigma pig mucus nanoparticle suspensions were gently stirred in 45 
mg/ml sigma pig mucus without G-blocks treatment (Stirred → Nanoparticle 
suspensions were mixed into mucus samples). (Data analysis is provided in Chapter 5, 
Figure 5.23, panels M, N, and O).  
As can be seen from Figure 3.17 A and B, there are differences between amine particle’s 
<MSD> and <Deff> plots vs. carboxylate particle’s <MSD> and <Deff> plots over time 
scales. The amine particle displayed higher transport rate than carboxylate particle did. 
The differences were reduced at longer time scales, and that were appeared by overlapped 
mean MSD (<MSD>) and mean Deff (<Deff>) plots for both amine and carboxylate particles 
(Figure 3.17 A and B). 
Importantly, amine particle showed greater mobility at shorter timescales but more hindered 
at longer timescales, while, carboxylate particle motion were more linear over time scale and 
got closer to amine plot at the end of time scale (Figure 3.17 A and B). 
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Amine nanoparticle <MSD> vs. COOH nanoparticle <MSD>
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Figure 3.17: Transport of amine particle versus carboxylate particle in sigma pig mucus. (A) 
Ensemble-averaged mean square displacement (<MSD>) and (B) effective diffusivity 
(<Deff>) versus time scale for amine and carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus contains. Data represents average MSD and Deff values for 100 nanoparticles were 
obtained at 73-ms time interval (Data analysis are shown in Chapter 5, Figure 5.25, panels B, 
C, and D and in Figure 5.23, panels M, N, and O).                                 
3.12.1 Discussion  
 
We observed that, nanoparticle motion in mucus matrix is dependent of their surface 
chemistry. This assumption is verified by gentle stirring amine and carboxylate nanoparticles 
in 45 mg/ml sigma pig mucus.  
Wang and co-worker, 2011 characterized the influence of synthetic particles on the mucus 
mesh networks.  They reported that, both particle concentration and surface chemistry are 
critical contributors in compromising the mucus barrier. They observed that, high 
concentration of mucoadhesive nanoparticles (MAP) can increase pore size in mucus through 
the crosslinking of bundling of mucus fibers, allowing greater penetration of foreign particles 
across mucus [3]. 
This study produced results which corroborate the findings of Wang and co-workers, that 
suggested the effect of surface chemistry as key factor for particle motion through mucus 
network [3]. 
Siguerdsson and et al showed that, size filtering and interaction filtering are two major 
mechanisms that may prevent nanoparticle to diffuse freely through mucus. Size filtering 
A B 
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mechanism could not be considered here, as all nanoparticles used in this study had the same 
size (200 nm in diameter). Interaction filtering stops nanoparticle transport based on 
nanoparticle surface chemistry and its interaction with mucus components. Therefore, 
nanoparticles with strong interaction within mucus components could not cross the mucus 
barrier and being trapped in mucus network, whereas, nanoparticle with weak degree of 
interaction within mucus components could pass the mucus elements without being trapped 
[7]. This finding by Siguerdsson et al corroborates with my ideas that is presented in Figure 
3.12.  
As shown in Figure 3.18 upon adding nanoparticle (here amine nanoparticles with positive 
surface charge) to mucus matrix, the architecture of mucus altered and forms bundles around 
particle, so particle would not move up stream the mucus and being trapped in mucus fibers. 
That would be due to ionic interaction between positively charged amine particle and 
negatively charged mucus network which lead particle to attach to mucus elements. 
Therefore, at longer time scales mucus become thicker and particles trap in mucus bundles, 
eventually particles will not able to move further in mucus mesh.                  
                              
  Figure 3.18: Schematic illustration of nanoparticle induced disruption of mucus [44]. 
Munkhopadhyay and colleagues reported that, polystyrene nanoparticles labeled with amine 
or COOH functional groups can assemble ordered structures on hydrophobic surfaces in 
liquid media [45]. 
Taken together, our results suggest that, nanoparticle motion can be influenced by labeling 
nanoparticle with functional groups like amine and carboxylate in mucus networks must 
likely due to formation of hydrophobic bond with negatively charge glycosylated segments 
along mucus fibers. Results suggest that G-blocks may reduce particle mobility at short time 
scale by interacting with this process.  
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3.13 Trajectory patterns of nanoparticle over time scales 
 
Observations at short time scales show movement over short distances. Trajectory patterns at 
short time scales could reflect particle interaction with the matrix architecture or moving 
within network pores but are unlikely to show particles crossing matrix pores elements 
(Figure 3.19 A). 
As long as time scales rise, nanoparticles face with greater barrier movement, being trapped 
in mucus fibers or wrapped around mucus bundles, result in impeding or vibrating 
nanoparticle motion in mucus network (Figure 3.19 B, blue and black arrows respectively). 
In addition, nanoparticle could exhibit diffusive movement through mucus matrix over time 
scales if nanoparticle avoided mucoadhesive interaction in this biological system (Figure 3.19 
B, orange arrow). 
If the matrix architecture was more open such long time scale, particle diffusion would be 
more  higher. Although, amine particle may alter the matrix architecture this did not result in 
diffusive motion at longer time scales. This may be because the particle plus mucin interact 
creates a matrix that is less penetrable over longer time scales. 
 
 
         
       Figure 3.19: Representative trajectories of nanoparticles in mucus over time scale. 
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Chapter 4 
Conclusion 
 
Mucus barrier is complex and poses a crucial limit to nanoparticle diffusion. To overcome 
barrier properties of mucosal layer, nanoparticle needs to cross the mucus elements. 
A key success in nanoparticle transport is to avoid adhesive interaction within mucus 
components. Results of this study indicate that, G-blocks have enough potential to engineer 
nanoparticle in order to traverse mucus matrix and reach targeted sites in the body. 
Reduction of barrier properties of the mucus layer would be associated to G-blocks ability to 
alter mucus rheology in a favorable manner to uptake nanoparticle. 
Whethear the barrier is decresess or increases by G-blocks depends on amount of G-blocks, 
Nanoparticle surface, addition of G-blocks in mucus matrix, as well as time scale. 
Such an improvement in nanoparticle transport through mucus blanket can lead to innovative 
drug delivery system for site specific target drug release, in order to combat against 
respiratory disease particularly cystic fibrosis disorder. 
The data presented here may be consistant with a model where G-blocks alter the mucus 
barrier architecture. This study must be repeated in ex vivo native matricses because it has 
been clearly shown here that the matrix components is critical to the barrier properties.        
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Chapter 5 
Data analysis 
5.1 The motion of carboxylate-modified nanoparticles in sigma pig mucus 
 
To determine nanoparticles motion in sigma pig mucus, multiple particle tracking technique 
was used. The following sample was studied, 
 Carboxylate nanoparticles were added on top left side of chamber contains 45 mg/ml 
sigma pig mucus (Unstirred) (Data analysis is shown in Figure 5.1). 
Changes on x and y positions of nanoparticle trajectories were imaged by confocal 
microscope and were processed with Image J plugin software. The mean square displacement 
(MSD) was calculated and used to calculate effective diffusivity (Deff).  
The averaged-mean square displacement (<Deff>) and average effective diffusivity (<Deff>) 
are presented in Figure 5.1. As can be seen from Figure 5.1, unstirred COOH nanoparticles 
show sub-diffusive mobility in 45 mg/ml sigma pig mucus. 
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Three replicate experiments were conducted at the same condition. There was a large 
variation in the individual particle trajectories and therefore MSD and Deff values which 
resulted in variability in the mean MSD and Deff values for 3 replicates. 
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Figure 5.1: The motion of unstirred carboxylate nanoparticle in sigma pig mucus. Duplicate 
ensemble mean square displacement (MSD) (J, M), effective diffusivity (K, N), and mean 
MSD (MSD) (solid line) plus mean (Deff) (dashed line) (L, O) for 50 unstirred COOH-
modified nanoparticles in 45 mg/ml sigma pig mucus.  
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Figure 5.2 Provides duplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 100 
unstirred COOH-modified nanoparticles in 45 mg/ml sigma pig mucus by combing L and O 
panels from 5.1. 
In order to quantify if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.2: Duplicate combined MSD and Deff plots for unstirred carboxylate nanoparticle 
in sigma pig mucus. Ensemble-averaged mean square displacement <MSD> (solid lines) and 
mean effective diffusivities <Deff> (dashed lines) of 100 stirred carboxylate nanoparticles 
(200 nm in diameter) in 45 mg/ml sigma pig mucus provided by two replicated experiments 
(this figure is combined plot of L, and O from Figure 5.1 as function of time scale). 
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To quantify whether these two repeated mean MSD (<MSD>) and mean Deff (<Deff>) 
values can be treated as same data set, the maximum and minimum MSD and Deff values of 
50 stirred COOH-modified nanoparticles were compared for all group of results (duplicate 
experiments) and are shown in Figure 5.3 A ,B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these two replicates satisfy the applied criteria and can be treated as a single data set 
(See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.3: Maximum and minimum MSD and Deff values from duplicate experiments for 
unstirred carboxylate nanoparticle in sigma pig mucus. Panel A present max and min MSD 
values for 100 carboxylate particles in 45 mg/ml sigma pig mucus between 0.1 to 10 second 
time scales, and panel B show max and min Deffs values for 100 carboxylate particles in 45 
mg/ml sigma pig mucus between 0.1 to 10 second time scales. 
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5.2 The effect of G-blocks treatment on carboxylate nanoparticles motion in sigma pig 
mucus by MPT 
 
The motion of nanoparticles was investigated in sigma pig mucus using multiple particle 
tracking. Therefore, the following sample taken in account, 
 Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and nanoparticle 
suspensions were gently stirred in 45 mg/ml sigma pig mucus (stirred → nanoparticle 
suspensions were mixed into mucus sample) (Data analysis is provided in Figure 5.4). 
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Figure 5.4: The motion of stirred carboxylate nanoparticle treated with G-blocks in sigma 
pig mucus. Triplicate ensemble mean square displacement (MSD) (P, S, V), effective 
diffusivity (Q, T, W), and mean MSD (MSD) (solid line) plus mean (Deff) (dashed line) (R, 
U, X) for 50 stirred carboxylate nanoparticles treated with 0.04 mg/ml G-blocks in 45 mg/ml 
sigma pig mucus.  
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Figure 5.5 Provides triplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 150 stirred 
carboxylate-modified nanoparticles in 45 mg/ml sigma pig mucus by combing R, U, and X 
panels from the Figure 5.4. 
In order to validate if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.5: Triplicate combined MSD and Deff plots for stirred carboxylate nanoparticle 
treated with G-blocks in sigma pig mucus. Ensemble-averaged mean square displacement 
<MSD> (solid lines) and mean effective diffusivities <Deff> (dashed lines) of 150 
carboxylate nanoparticles (200 nm in diameter) treated with 0.04 mg/ml G-blocks in 45 
mg/ml sigma pig mucus provided by three replicated experiments (This Figure is Combined 
plot of R, U, and X from Figure 5.4 as function of time scale). 
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5.3 The comparison between triplicate maximum and minimum MSD and Deff values 
for 150 COOH-modified nanoparticles treated with G-blocks 
 
To quantify whether these three repeated mean MSD (<MSD>) and mean Deff (<Deff>) 
values can be treated as same data set, the maximum and minimum MSD and Deff values of 
50 stirred COOH-modified nanoparticles were compared for all group of results (triplicate 
experiments) and are shown in Figure 5.6 A ,B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these three replicates satisfy the applied criteria and can be treated as a single data 
set (See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.6: Maximum and minimum MSD and Deff values from triplicate experiments for 
stirred carboxylate nanoparticle treated with G-blocks in sigma pig mucus. Panel A presents 
maximum and minimum MSD values for 150 stirred carboxylate-modified nanoparticles 
treated with 0.04 mg/ml G-blocks in 45 mg/ml sigma pig mucus between 0.1 to 10 second 
time scales, and panel B shows mean maximum and minimum Deffs values for 150 
carboxylate-modified nanoparticles in 45 mg/ml sigma pig mucus between 0.1 to 10 second 
time scales.  
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5.4 The transport of carboxylate nanoparticles in the presence of G-blocks in sigma pig 
mucus 
The transport of carboxylate nanoparticles treated in sigma pig mucus was studied in the 
presence of G-blocks using multiple particle tracking technique. Therefore, the following 
sample was investigated, 
 Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and were added gently 
on top left side of chamber contains 45 mg/ml sigma pig mucus (unstirred) (Data 
analysis is provided in Figure 5.7). 
The mean square displacement (MSD) was calculated and used to calculate effective 
diffusivity (Deff). The averaged-mean square displacement (<Deff>) and mean Deff 
(<Deff>) values are shown in Figure 5.7. As can be seen from Figure 5.7, unstirred COOH 
nanoparticles which treated with 0.04 mg/ml G-blocks show sub-diffusive motion in 45 
mg/ml sigma pig mucus. 
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<MSD> and <Deff> for 50 particles + 0.04 mg/ml G-blocks
                         in 45 mg/ml sigma pig mucus
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                                                       (d)
Carboxylate particles + 0.04 mg/ml G-blocks in 45 mg/ml SPM
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Carboxylate particles + 0.04 mg/ml G-blocks in 45 mg/ml SPM
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<MSD> and <Deff> for 50 COOH particles + 0.04 mg/ml G-blocks
                              in 45 mg/ml sigma pig mucin
                        (Unstirred particles into the mucus)
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                                                      (g)
Carboxylate particles + 0.5 mg/ml G-blocks in 45 mg/ml SPM
                      (Unstirred particles into the mucus)
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Carboxylate particles + 0.04 mg/ml G-blocks in 45 mg/ml SPM
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Figure 5.7: The motion of unstirred carboxylate nanoparticle treated with G-blocks in sigma 
pig mucus. Triplicate ensemble mean square displacement (MSD) (a, d, g), effective 
diffusivity (b, e, h), mean MSD (MSD) (solid line), and mean (Deff) (dashed line) (c, f, i) for 
50 unstirred COOH-modified nanoparticles treated with 0.04 mg/ml G-blocks in 45 mg/ml 
sigma pig mucus.  
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Figure 5.8 provides triplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 150 
unstirred COOH-modified nanoparticles in 45 mg/ml sigma pig mucus by combing c, f, and i 
panels from Figure 5.7. 
In order to quantify if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria). 
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Figure 5.8: Triplicate combined MSD and Deff plots for unstirred carboxylate nanoparticle 
treated with G-blocks in sigma pig mucus.  Ensemble-averaged mean square displacement 
<MSD> (solid lines) and mean effective diffusivities <Deff> (dashed lines) of 150 unstirred 
carboxylate particles (200 nm in diameter) in 45 mg/ml Sigma pig mucus provided by three 
replicated experiments (this figure is combined plot of c, f and i from Figure 5.7 as function 
of time scale). 
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To quantify whether these three repeats mean MSD (<MSD>) and mean Deff (<Deff>) 
values can be treated as same data set, we compared maximum and minimum MSD and Deff 
values of COOH-modified nanoparticles from the each triplicate experiment and are shown in 
Figure 5.9, A ,B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these three replicates satisfy the applied criteria and can be treated as a single data 
set (See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.9: Maximum and minimum MSD and Deff values from triplicate experiments for 
unstirred carboxylate nanoparticle treated with G-blocks in sigma pig mucus. Panel A 
Presents maximum and minimum MSD values for 150 unstirred carboxylate nanoparticle in 
45 mg/ml sigma pig mucus between 0.1 to 10 second time scales, Panel B shows maximum 
and minimum Deffs values for 150 unstirred carboxylate particles in 45 mg/ml sigma pig 
mucus between 0.1 to 10 second time scales. 
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5.5 The motion of carboxylate nanoparticles in sigma pig mucus + polymeric mucus by 
MPT   
 
The motion of nanoparticles was investigated in sigma pig mucus + polymeric mucus using 
multiple particle tracking. Therefore, the following sample taken in account, 
 Carboxylate nanoparticles were gently stirred in 45 mg/ml sigma pig mucus + 
polymeric mucus (30 and 15 mg/ml respectively) (stirred → nanoparticle suspensions 
were mixed into mucus sample) (Data analysis is provided in Figure 5.10). 
The mean square displacement (MSD) was calculated and used to calculate effective 
diffusivity (Deff). The averaged-mean square displacement (<Deff>) and mean Deff 
(<Deff>) values are shown in Figure 5.10. As can be seen from Figure 5.10, unstirred COOH 
nanoparticles that show sub-diffusive motion in 45 mg/ml sigma pig mucus + polymeric 
mucus. 
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<MSD> and <Deff> for 50 particles in 45 mg/ml SPM + PM
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Figure 5.10: The motion of stirred carboxylate nanoparticle in sigma pig mucus + polymeric 
mucus. Duplicate ensemble mean square displacement (MSD) (j, m), effective diffusivity (k, 
n), mean MSD (MSD) (solid line) and mean (Deff) (dashed line) (l, o) for 50 stirred COOH-
modified nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus. 
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Figure 5.11 provides duplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 100 stirred 
COOH-modified nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus by combing 
l and o and panels from the Figure 5.10. 
In order to quantify if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria). 
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Figure 5.11: Duplicate combined MSD and Deff plots for stirred carboxylate nanoparticle in 
sigma pig mucus + polymeric mucus. Ensemble-averaged mean square displacement <MSD> 
(solid lines) and mean effective diffusivities <Deff> (dashed lines) of carboxylate-modified 
nanoparticles (200 nm in diameter) in 45 mg/ml sigma pig mucus + polymeric mucus 
provided by two replicated experiments (this Figure is combined plot of l, and o from Figure 
5.10 as function of time scale). 
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To quantify whether these two repeats mean MSD (<MSD>) and mean Deff (<Deff>) values 
can be treated as same data set, we compared maximum and minimum MSD and Deff values 
of 50 stirred COOH-modified nanoparticles from triplicate experiments and are shown in 
Figure 5.12 A and B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these two replicates satisfy the applied criteria and can be treated as a single data set 
(See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.12: Maximum and minimum MSD and Deff values from duplicate experiments for 
stirred carboxylate in sigma pig mucus + polymeric mucus. Panel A presents maximum and 
minimum MSD values for 100 stirred carboxylate particles in 45 mg/ml sigma pig mucus + 
polymeric mucus between 0.1 to 10 second time scales, Panel B presents maximum and 
minimum Deffs values for 100 stirred carboxylate particles in 45 mg/ml sigma pig mucus + 
polymeric mucus between 0.1 to 10 second time scales. 
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5.6 The transport of carboxylate nanoparticles in sigma pig mucus + polymeric mucus 
 
The motion of nanoparticles was investigated in sigma pig mucus + polymeric mucus using 
multiple particle tracking. Therefore, the following sample taken in account, 
 Carboxylate nanoparticles were added on top left side of chamber contains 45 mg/ml 
sigma pig mucus + polymeric mucus (30 and 15 mg/ml respectively) (unstirred) (Data 
analysis is provided in Figure 5.10). 
The mean square displacement (MSD) was calculated and used to calculate effective 
diffusivity (Deff). The averaged-mean square displacement (<Deff>) and mean Deff 
(<Deff>) values are shown in Figure 5.13. As can be seen from Figure 5.13, unstirred COOH 
nanoparticles that show sub-diffusive motion in 45 mg/ml sigma pig mucus + polymeric 
mucus. 
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Figure 5.13: The motion of unstirred carboxylate nanoparticle in sigma pig mucus + 
polymeric mucus. Duplicate ensemble mean square displacement (MSD) (p, s), effective 
diffusivity (q, t), and mean MSD (MSD) (solid line) plus mean (Deff) (dashed line) (r. u) for 
50 COOH-modified nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus.  
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Figure 5.14 Provides duplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 100 
COOH-modified nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus + by 
combing r, and u panels from the Figure 5.13. 
In order to determine if results were representative, a set of exclusion criteria was applied 
over all duplicate results to determine if they could be considered as one data set (refer to 
Chapter 3, section 3.2, Exclusion criteria). 
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Figure 5.14: Duplicate combined MSD and Deff plots for unstirred carboxylate nanoparticle 
in sigma pig mucus + polymeric mucus. Ensemble-averaged mean square displacement 
<MSD> (solid lines) and mean effective diffusivities <Deff> (dashed lines) of 100 unstirred 
carboxylate-modified nanoparticles (200 nm in diameter) in 45 mg/ml sigma pig mucus + 
polymeric mucus provided by two replicated experiments (This Figure is combined plot of r, 
and u from Figure 5.13 as function of time scale). 
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To quantify whether these two repeats mean MSD (<MSD>) and mean Deff (<Deff>) values 
can be treated as same data set, we compared maximum and minimum MSD and Deff values 
of 100 unstirred carboxylate nanoparticles from the each duplicate experiments and are 
shown in Figure 5.15 A, B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these two replicates satisfy the applied criteria and can be treated as a single data set 
(See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.15: Maximum and minimum MSD and Deff values from duplicate experiments for 
unstirred carboxylate in sigma pig mucus + polymeric mucus. Panel A presents maximum 
and minimum MSD values for 100 unstirred carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus + polymeric mucus between 0.1 to 10 second time scale, Panel B presents maximum 
and minimum Deff values for 100 unstirred carboxylate particles in 45 mg/ml sigma pig 
mucus + polymeric mucus between 0.1 to 10 second time scale. 
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5.7 The motion of carboxylate nanoparticle treated with G-blocks in sigma pig mucus + 
polymeric mucus 
The motion of nanoparticles was investigated in sigma pig mucus + polymeric mucus in the 
presence of G-blocks using multiple particle tracking. Therefore, the following sample taken 
in account, 
 Carboxylate nanoparticles treated with 0.04 mg/ml G-blocks and nanoparticle 
suspensions were gently stirred in 45 mg/ml sigma pig mucus + polymeric mucus (30 
and 15 mg/ml respectively) (stirred → nanoparticle suspensions were mixed into 
mucus sample) (Data analysis is provided in Figure 5.10). 
The mean square displacement (MSD) was calculated and used to calculate effective 
diffusivity (Deff). The averaged-mean square displacement (<Deff>) and mean Deff 
(<Deff>) values are shown in Figure 5.16. As can be seen from Figure 5.16, unstirred COOH 
nanoparticles which treated with 0.04 mg/ml G-blocks show sub-diffusive motion in 45 
mg/ml sigma pig mucus + polymeric mucus. 
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Figure 5.16: The motion of stirred carboxylate nanoparticle treated with G-blocks in sigma 
pig mucus + polymeric mucus. Duplicate ensemble mean square displacement (MSD) (U, X), 
effective diffusivity (V, Y), mean MSD (MSD) (solid line) and mean (Deff) (dashed line) 
(W, Z) for 50 stirred COOH-modified nanoparticles treated with 0.04 mg/ml G-blocks in 45 
mg/ml sigma pig mucus + polymeric mucus.  
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Figure 5.17 provides duplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 100 stirred 
COOH-modified nanoparticles treated with 0.04 mg/ml in 45 mg/ml sigma pig mucus + 
polymeric mucus  by combing W, and Z panels from the Figure 5.16. 
In order to quantify if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria). 
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Figure 5.17: Duplicate combined MSD and Deff plots for stirred carboxylate nanoparticle 
treated with G-blocks in sigma pig mucus + polymeric mucus. Ensemble-averaged mean 
square displacement <MSD> (solid lines) and mean effective diffusivities <Deff> (dashed 
lines) of 100 stirred carboxylate particles (200 nm in diameter) in 45 mg/ml sigma pig mucus 
+ polymeric mucus provided by two replicated experiments (This Figure is combined plot of 
W, and Z from Figure 5.16 as function of time scale). 
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To quantify whether these two repeats mean MSD (<MSD>) and mean Deff (<Deff>) values 
can be treated as same data set, we compared maximum and minimum MSD and Deff values 
of 50 COOH-modified nanoparticles from the each triplicate experiment and are shown in 
Figure 5.18 A and B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these two replicates satisfy the applied criteria and can be treated as a single data set 
(See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.18: Maximum and minimum MSD and Deff values from duplicate experiments for 
stirred carboxylate treated with G-blocks in sigma pig mucus + polymeric mucus.  Panel A 
presents maximum and minimum MSD values for 100 stirred carboxylate-modified 
nanoparticles in 45 mg/ml sigma pig mucus + polymeric mucus between 0.1 to 10 second 
time scales, (A), and panel B presents maximum and minimum Deff values for 100 stirred 
carboxylate-modified nanoparticles treated with 0.04 mg/ml G-blocks in 45 mg/ml sigma pig 
mucus + polymeric mucus between 0.1 to 10 second time scales. 
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The motion of nanoparticles was investigated in sigma pig mucus + polymeric mucus using 
multiple particle tracking. Therefore, the following sample taken in account, 
 Carboxylate nanoparticles were treated with 0.04 mg/ml G-blocks and were added on 
top left side of chamber contains 45 mg/ml sigma pig mucus + polymeric mucus (30 
and 15 mg/ml respectively) (unstirred) (Data analysis is provided in Figure 5.19). 
The mean square displacement (MSD) was calculated and used to calculate effective 
diffusivity (Deff). The averaged-mean square displacement (<Deff>) and mean Deff 
(<Deff>) values are shown in Figure 5.19. As can be seen from Figure 5.19, unstirred COOH 
nanoparticles treated with 0.04 mg/ml G-blocks which show sub-diffusive motion in 45 
mg/ml sigma pig mucus + polymeric mucus. 
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Figure 5.19: The motion of unstirred carboxylate nanoparticle treated with G-blocks in 
sigma pig mucus + polymeric mucus. Duplicate ensemble mean square displacement (MSD) 
(a1, d1), effective diffusivity (b1, e1), and mean MSD (MSD) (solid line) plus mean (Deff) 
(dashed line) (c1, f1) for 50 unstirred COOH-modified nanoparticles treated with 0.04 mg/ml 
G-blocks in 45 mg/ml sigma pig mucus + polymeric mucus.  
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Figure 5.20 provides duplicate mean MSD (<MSD>) and mean Deff (<Deff>) for 100 
unstirred COOH-modified nanoparticles trearted with 0.04 mg/ml G-blocks in 45 mg/ml 
sigma pig mucus + polymeric mucus by combing c1, and f1 panels from the Figure 5.19. 
In order to quantify if results were representative, a set of exclusion criteria was applied over 
all triplicate results to determine if they could be considered as one data set (refer to Chapter 
3, section 3.2, Exclusion criteria). 
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Figure 5.20: Duplicate combined MSD and Deff plots for unstirred carboxylate nanoparticle 
treated with G-blocks in sigma pig mucus + polymeric mucus .Ensemble-averaged mean 
square displacement <MSD> (solid lines) and mean effective diffusivities <Deff> (dashed 
lines) of 100 unstirred carboxylate nanoparticles (200 nm in diameter) treated with 0.04 
mg/ml G-blocks in 45 mg/ml sigma pig mucus + polymeric mucus provided by two 
replicated experiments (This Figure is combined plot of c1, and f1 from Figure 5.19 as 
function of time scale). 
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To quantify whether these two repeats mean MSD (<MSD>) and mean Deff (<Deff>) values 
can be treated as same data set, we compared maximum and minimum MSD and Deff values 
of 100 unstirred COOH-modified nanoparticles from the each duplicate experiment and are 
shown in Figure 5.21 A and B. 
Considering points 1, 2, and 3 of defined exclusion criteria, results are representative, and 
therefore these two replicates satisfy the applied criteria and can be treated as a single data set 
(See applied exclusion criteria in Chapter 3, section 3.2, Exclusion criteria, page 47). 
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Figure 5.21: Maximum and minimum MSD and Deff values from duplicate experiments for 
unstirred carboxylate treated with G-blocks in sigma pig mucus + polymeric mucus. Panel A 
presents mean maximum and minimum MSD values for 100 unstirred carboxylate 
nanoparticles treated with 0.04 mg/ml G-blocks in 45 mg/ml sigma pig mucus + polymeric 
mucus between 0.1 to 10 second time scales , and panel B shows mean maximum and 
minimum Deffs values for 100 unstirred carboxylate-modified nanoparticles treated with 0.04 
mg/ml G-blocks in 45 mg/ml sigma pig mucus + polymeric mucus between 0.1 to 10 second 
time scales. 
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5.8 Real-time dynamic motion of carboxylate-modified nanoparticles in sigma pig 
mucus contains G-blocks 
 
The transport of carboxylate-modified nanoparticles was investigated in mucus samples using 
multiple particle tracking technique (MPT). 
The following samples were studied, 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus without G-blocks 
treatment (Data analysis is provided in Chapter 5, Figure 5.23, panels M, N, and O) 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.04 
mg/ml G-blocks (Data analysis is provided in Chapter 5, Figure 5.22, panels A, B, 
and C) 
 Carboxylate nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.5 
mg/ml G-blocks (Data analysis is provided in Chapter 5, Figure 5.22, panels D, E, and 
F). 
For all three conditions above (1, 2, and 3), nanoparticle suspensions were gently stirred in 
mucus samples (Stirred → nanoparticle suspensions were mixed in mucus samples). 
Figure 5.22 shows mean square displacements (MSD), and average mean square 
displacement (<MSD>) of 100 COOH-modified particles in 45 mg/ml sigam pig mucus. The 
MSD values allowed us to determine effective diffusivity (Deff) (MSD/4*T). (Note that all 
values are plotted as function of time scale). 
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Figure 5.22: Real-time dynamic motion of carboxylate nanoparticle in sigma pig mucus 
contains G-blocks. Ensemble  MSD, Deff, mean MSD (<MSD>), and mean Deff (<Deff>) 
(A, B, C) for 100 carboxylate-modified nanoparticles treated with 0.04 mg/ml G-blocks in 45 
mg/ml sigma pig mucus, and The MSD, Deff, mean MSD (<MSD>), and mean Deff 
(<Deff>) (D, E, F) for 100 carboxylate-modified nanoparticles treated with 0.5 mg/ml G-
blocks  in 45 mg/ml sigma pig mucus. 
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5.9 Real-time dynamic motion of carboxylate nanoparticle treated with G-blocks in 
sigma pig mucus  
 
The transport of carboxylate-modified nanoparticles was investigated in 45 mg/ml sigma pig 
mucus using multiple particle tracking (MPT).  
The following samples were studied, 
 Carboxylate nanoparticle suspensions without G-blocks treatment were gently stirred 
in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions were mixed in 
mucus) (Data analysis is provided in Chapter 5, Figure 5.23, panels M, N, and O). 
 Carboxylate nanoparticle suspensions were mixed with 0.04 mg/ml G-blocks and 
were stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions 
were mixed in mucus) (Data analysis is shown in Chapter 5, Figure 5.23, panels G, H, 
and I ) 
 Carboxylate nanoparticle suspensions were mixed with 0.5 mg/ml G-blocks and were 
stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions were 
mixed in mucus) (Data analysis is presented in Chapter 5, Figure 5.23, panels J, K,  
and L). 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
102 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
 
                                   G
100 COOH particles + 0.04 mg/ml G-blocks
            in 45mg/ml Sigma pig mucus
Time scale (s)
0.01 0.1 1 10 100
M
S
D
 (
m
2
)
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
   
                                   H
100 COOH particles + 0.04 mg/ml G-blocks
             in 45 mg/ml Sigma pig mucus
Time sacle (s)
0.01 0.1 1 10 100
D
e
ff
 (
m
2
/s
)
1e-4
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
    
                                                    I
<MSD> and <Deff> for 100 COOH particles + 0.04 mg/ml G-blocks
                               in 45 mg/ml Sigma pig mucus
Time sacle (s)
0.01 0.1 1 10 100
<
M
S
D
>
 (
m
2
) 
a
n
d
 <
D
e
ff
>
 (
m
2
/s
)
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
<MSD> vs time scale
<Deff> vs time scale
                                 J
100 COOH particles + 0.5 mg/ml G-blocks
          in 45 mg/ml sigma pig mucus
Time scale (s)
0.01 0.1 1 10 100
M
S
D
 (
m
2
)
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
   
                                           K
100 COOH particle trajectories + 0.5 mg/ml G-blocks
                    in 45 mg/ml Sigma pig mucin
Time scale (s)
0.01 0.1 1 10 100
D
e
ff
 (
m
2
/s
)
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
     
                                              L
<MSD> and <Deff> for 100 COOH particles + 0.5 mg/ml
                       in 45 mg/ml Sigma pig mucin
Time sacle (s)
0.01 0.1 1 10 100
<
M
S
D
>
 (
m
2
) 
a
n
d
 <
D
e
ff
>
 (
m
2
/s
)
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
<MSD> vs time scale
<Deff> vs time scale
 
                              M
100 COOH particles without G-blocks
        in 45 mg/ml Sigma pig mucus
   
Time scale (s)
0.01 0.1 1 10 100
M
S
D
 (
m
2
)
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
   
                              N
100 COOH particles without G-blocks
       in 45 mg/ml Sigma pig mucus
Time scale (s)
0.01 0.1 1 10 100
D
e
ff
 (
m
2
/s
)
1e-4
1e-3
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
     
                                                   O
<MSD> and <Deff> for 100 COOH particles without G-blocks
                            in 45 mg/ml Sigma pig mucus
Time sacle (s)
0.01 0.1 1 10 100
<
M
S
D
>
 (
m
2
) 
a
n
d
 <
D
e
ff
>
 (
m
2
/s
)
1e-2
1e-1
1e+0
1e+1
1e+2
1e+3
1e+4
1e+5
<MSD> vs time scale
<Deff> vs time scale
 
Figure 5.23: Real-time dynamic motion of carboxylate nanoparticle treated with G-blocks in 
sigma pig mucus. Ensemble MSD, Deff, <MSD>, and <Deff> values of 100 COOH-modified 
nanoparticles in 45 mg/ml of sigma pig mucus. The MSD, Deff, mean MSD (<MSD>), and 
mean Deff (<Deff>) (G, H, I) in 45 mg/ml sigma pig mucus mixed with 0.04 mg/ml G-
blocks, The MSD, Deff, mean MSD (<MSD>), and mean Deff (<Deff>) (J, K, L) in 45 
mg/ml sigma pig mucus mixed with 0.5 mg/ml G-blocks, The MSD, Deff, mean MSD 
(<MSD>), and mean Deff (<Deff>) (M, N, O) for carboxylate nanoparticles with no G-
blocks treatment in 45 mg/ml sigma pig mucus.  
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5.10 The movement of amine nanoparticles in sigma pig mucus contains G-blocks 
 
To deepen our knowledge about the interaction between nanoparticles and mucus network, 
we used the amine-modified nanoparticles for our experiments as well. The mean square 
displacement (MSD), and effective diffusivity (Deff) of 100 amine-modified nanoparticles 
calculated, and plotted versus time scale.  
Therefore, the following studies were taken into account, 
 Amine nanoparticles motion in 45 mg/ml sigma pig mucus without G-blocks 
treatment (Data analysis is provided in Chapter 5, Figure 5.25, panels B, C, and D) 
 Amine nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.04 mg/ml G-
blocks (Data analysis is provided in Chapter 5, Figure 5.24, panels V, W, and X) 
 Amine nanoparticles motion in 45 mg/ml sigma pig mucus mixed with 0.5 mg/ml G-
blocks (Data analysis is provided in Chapter 5, Figure 5.24, panels Y, Z, and A). 
Figure 5.24 presents mean square displacement (MSD), mean MSD (<MSD>), effective 
diffusivity (Deff), and mean Deff (<Deff>) values of amine-modified nanoparticles in 45 
mg/ml sigma pig mucus samples mixed with 0.04 mg/ml and 0.5 mg/ml G-blocks 
respectively. 
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Figure 5.24: The movement of amine nanoparticle in sigma pig mucus contains G-blocks. 
Ensemble MSD, Deff, <MSD>, and <Deff> values of 100 amine-modified nanoparticles in 
45 mg/ml of Sigma pig mucus. The MSD, Deff, mean MSD (<MSD>), and mean Deff 
(<Deff>) (P, Q, R) in 45 mg/ml sigma pig mucus mixed with 0.04 mg/ml G-blocks, The 
MSD, Deff, mean MSD (<MSD>), and mean Deff (<Deff>) (S, T, U) in 45 mg/ml sigma pig 
mucus mixed with 0.5 mg/ml G-blocks.  
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5.11 The movement of amine nanoparticle treated with G-blocks in sigma pig mucus 
 
The motion of carboxylate-modified nanoparticles (treated with G-blocks concentrations) 
was investigated in sigma pig mucus using MPT. 
Therefore, the following samples were studied, 
 Amine nanoparticle suspensions without G-blocks treatment were gently stirred in 45 
mg/ml sigma pig mucus (stirred → nanoparticle suspensions were mixed in mucus) 
(Data analysis is provided in Chapter 5, Figure 5.25, panels B, C, and D). 
 Amine nanoparticle suspensions were mixed with 0.04 mg/ml G-blocks and were 
stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions were 
mixed in mucus) (Data analysis is shown in Chapter 5, Figure 5.25, panels V, W, and 
X) 
 Amine nanoparticle suspensions were mixed with 0.5 mg/ml G-blocks and were 
stirred gently in 45 mg/ml sigma pig mucus (stirred → nanoparticle suspensions were 
mixed in mucus) (Data analysis is presented in Chapter 5, Figure 5.25, panels Y, Z, 
and A). 
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Figure 5.25: The movement of amine nanoparticle treated with G-blocks in sigma pig 
mucus. Ensemble MSD, Deff, <MSD>, and <Deff> values of 100 amine-modified particles 
in 45 mg/ml of Sigma pig mucus. The MSD, Deff, and mean MSD (<MSD>) mean Deff 
(<Deff>) (V, W, X) for amine nanoparticles treated with 0.04 mg/ml G-blocks in 45 mg/ml 
sigma pig mucus, The MSD, Deff, and mean MSD (<MSD>) mean Deff (<Deff>) (Y, Z, A) 
for amine nanoparticles treated with 0.5 mg/ml G-blocks in 45 mg/ml sigma pig mucus, The 
MSD, Deff, mean MSD (<MSD>), and mean Deff (<Deff>) (B, C, D) for amine 
nanoparticles with no G-blocks treatment in 45 mg/ml sigma pig mucus. 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
  107 
 
Bibliography 
1. Ensign, L.M., et al., Mucus penetrating nanoparticles: biophysical tool and method of 
drug and gene delivery. Adv Mater, 2012. 24(28): p. 3887-94. 
2. Cone, R.A., Barrier properties of mucus. Adv Drug Deliv Rev, 2009. 61(2): p. 75-85. 
3. Wang, Y.Y., et al., Mucoadhesive nanoparticles may disrupt the protective human 
mucus barrier by altering its microstructure. PLoS One, 2011. 6(6): p. e21547. 
4. Ashida, H., et al., Bacteria and host interactions in the gut epithelial barrier. Nat Chem 
Biol, 2012. 8(1): p. 36-45. 
5. Lai, S.K., et al., Micro- and macrorheology of mucus. Adv Drug Deliv Rev, 2009. 
61(2): p. 86-100. 
6. Ensign, L.M., R. Cone, and J. Hanes, Oral drug delivery with polymeric 
nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev, 2012. 64(6): p. 557-
70. 
7. Sigurdsson, H.H., J. Kirch, and C.M. Lehr, Mucus as a barrier to lipophilic drugs. Int 
J Pharm, 2013. 
8. Pepic, I., J. Lovric, and J. Filipovic-Grcic, How do polymeric micelles cross epithelial 
barriers? Eur J Pharm Sci, 2013. 
9. Button, B., et al., A periciliary brush promotes the lung health by separating the 
mucus layer from airway epithelia. Science, 2012. 337(6097): p. 937-41. 
10. Thornton, D.J., K. Rousseau, and M.A. McGuckin, Structure and function of the 
polymeric mucins in airways mucus. Annu Rev Physiol, 2008. 70: p. 459-86. 
11. Occhipinti, P. and P.C. Griffiths, Quantifying diffusion in mucosal systems by pulsed-
gradient spin-echo NMR. Adv Drug Deliv Rev, 2008. 60(15): p. 1570-82. 
12. Silva, C.A., et al., Interaction of chitosan and mucin in a biomembrane model 
environment. J Colloid Interface Sci, 2012. 376(1): p. 289-95. 
13. Dawson, M., et al., Transport of polymeric nanoparticle gene carriers in gastric 
mucus. Biotechnol Prog, 2004. 20(3): p. 851-7. 
     Mucus barrier components, challenges for nanoscale drug delivery 
108 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
14. Teubl, B.J., et al., The oral cavity as a biological barrier system: Design of an 
advanced buccal in vitro permeability model. Eur J Pharm Biopharm, 2013. 84(2): p. 386-93. 
15. Lavaud, M.C. and J. Trouillas, [The mucus: a medium of life]. Gynecol Obstet Fertil, 
2012. 40(1): p. 19-23. 
16. Lai, S.K., et al., Micro- and macrorheology of mucus. Advanced drug delivery 
reviews, 2009. 61(2): p. 86-100. 
17. Nordgard, C.T. and K.I. Draget, Oligosaccharides as modulators of rheology in 
complex mucous systems. Biomacromolecules, 2011. 12(8): p. 3084-90. 
18. Cone, R.A., Barrier properties of mucus. Advanced drug delivery reviews, 2009. 
61(2): p. 75-85. 
19. Lai, S.K., Y.Y. Wang, and J. Hanes, Mucus-penetrating nanoparticles for drug and 
gene delivery to mucosal tissues. Adv Drug Deliv Rev, 2009. 61(2): p. 158-71. 
20. Huang, F., et al., Quantitative nanoparticle tracking: applications to nanomedicine. 
Nanomedicine (Lond), 2011. 6(4): p. 693-700. 
21. Ensign, L.M., et al., Mucus penetrating nanoparticles: biophysical tool and method of 
drug and gene delivery. Advanced materials (Deerfield Beach, Fla.), 2012. 24(28): p. 3887-
94. 
22. Varela, J.A., et al., Quantifying size-dependent interactions between fluorescently 
labeled polystyrene nanoparticles and mammalian cells. J Nanobiotechnology, 2012. 10: p. 
39. 
23. Tong, S., et al., Engineering imaging probes and molecular machines for 
nanomedicine. Science China. Life sciences, 2012. 55(10): p. 843-61. 
24. Pison, U., et al., Nanomedicine for respiratory diseases. European journal of 
pharmacology, 2006. 533(1-3): p. 341-50. 
25. Kumar, A., X. Zhang, and X.J. Liang, Gold nanoparticles: Emerging paradigm for 
targeted drug delivery system. Biotechnology advances, 2012. 
26. Laroui, H., S.V. Sitaraman, and D. Merlin, Gastrointestinal delivery of anti-
inflammatory nanoparticles. Methods Enzymol, 2012. 509: p. 101-25. 
     Mucus barrier components, challenges for nanoscale drug delivery 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
  109 
 
27. Laroui, H., S.V. Sitaraman, and D. Merlin, Chapter six - Gastrointestinal Delivery of 
Anti-inflammatory Nanoparticles, in Methods in Enzymology, D. Nejat, Editor. 2012, 
Academic Press. p. 101-125. 
28. Draget, K.I. and C. Taylor, Chemical, physical and biological properties of alginates 
and their biomedical implications. Food Hydrocolloids, 2011. 25(2): p. 251-256. 
29. Borgogna, M., et al., On the Initial Binding of Alginate by Calcium Ions. The Tilted 
Egg-box Hypothesis. J Phys Chem B, 2013. 
30. Jorgensen, T.E., et al., Influence of oligoguluronates on alginate gelation, kinetics, 
and polymer organization. Biomacromolecules, 2007. 8(8): p. 2388-97. 
31. Sikorski, P., et al., Evidence for egg-box-compatible interactions in calcium-alginate 
gels from fiber X-ray diffraction. Biomacromolecules, 2007. 8(7): p. 2098-103. 
32. Flume, P.A. and D.R. Van Devanter, State of progress in treating cystic fibrosis 
respiratory disease. BMC Med, 2012. 10: p. 88. 
33. das Neves, J., et al., Interactions of microbicide nanoparticles with a simulated 
vaginal fluid. Mol Pharm, 2012. 9(11): p. 3347-56. 
34. Monnier, N., et al., Bayesian approach to MSD-based analysis of particle motion in 
live cells. Biophys J, 2012. 103(3): p. 616-26. 
35. Suh, J., M. Dawson, and J. Hanes, Real-time multiple-particle tracking: applications 
to drug and gene delivery. Adv Drug Deliv Rev, 2005. 57(1): p. 63-78. 
36. Suh, J., D. Wirtz, and J. Hanes, Efficient active transport of gene nanocarriers to the 
cell nucleus. Proc Natl Acad Sci U S A, 2003. 100(7): p. 3878-82. 
37. Suh, J., M. Dawson, and J. Hanes, Real-time multiple-particle tracking: applications 
to drug and gene delivery. Advanced drug delivery reviews, 2005. 57(1): p. 63-78. 
38. Fogg, F.J., et al., Characterization of pig colonic mucins. Biochem J, 1996. 316 ( Pt 
3): p. 937-42. 
39. Shotton, M., Confocal scanning microscopy and its applications for biological 
speciments. Jornal of Cell Science 94, 1989: p. 175-206. 
     Mucus barrier components, challenges for nanoscale drug delivery 
110 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
40. WIKIPEDIA, http://en.wikipedia.org/wiki/Exclusion criteria 
41. Lai, S.K., et al., Rapid transport of large polymeric nanoparticles in fresh undiluted 
human mucus. Proc Natl Acad Sci U S A, 2007. 104(5): p. 1482-7. 
42. Schuster, B.S., et al., Nanoparticle diffusion in respiratory mucus from humans 
without lung disease. Biomaterials, 2013. 34(13): p. 3439-46. 
43. Ensign, L.M., et al., Ex vivo characterization of particle transport in mucus secretions 
coating freshly excised mucosal tissues. Mol Pharm, 2013. 10(6): p. 2176-82. 
44. McGill, S.L. and H.D. Smyth, Disruption of the mucus barrier by topically applied 
exogenous particles. Mol Pharm, 2010. 7(6): p. 2280-8. 
45. Mukhopadhyay, R., et al., Ordering of binary polymeric nanoparticles on hydrophobic 
surfaces assembled from low volume fraction dispersions. J Am Chem Soc, 2007. 129(44): p. 
13390-1. 
 
 
  
     Mucus barrier components, challenges for nanoscale drug delivery 
*SPM= Sigma pig mucus, *PM= Polymeric mucus 
 
  111 
 
Appendixes  
 
Appendix A: Nanoparticles showed active motion 
 
As discussed earlier in result and discussion, chapter 3, the exclusion criteria applied in order 
to exclude any image series that showed apparent active transport, because nanoparticles 
must not exhibit active mobility in mucus matrix. Therefore, such a result would not be 
considered in this thesis and are given here, 
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Figure A.1: Shows active mobility of carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus + polymeric mucus. (A) Ensemble MSD value, and (B) Deff value obtained at 73-ms 
time intervals (Experiment 2, chamber 5). 
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Figure A.2: Shows active mobility of carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus + polymeric mucus. (A) Ensemble MSD value, and (B) Deff values obtained at 73-ms 
time intervals (Experiment 1, chamber 6). 
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Figure A.3: Shows active mobility of carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus + polymeric mucus. (A) Ensemble MSD value, and (B) Deff values obtained at 73-ms 
time intervals (Experiment 1, chamber 7). 
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Carboxylate particles + 0.04 mg/ml G-blocks in 45 mg/ml SPM + PM
                           (Unstirred particles into the mucus)
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Figure A.4: Shows active mobility of carboxylate nanoparticles in 45 mg/ml sigma pig 
mucus + polymeric mucus. (A) Ensemble MSD value, and (B) Deff values obtained at 73-ms 
time intervals (Experiment 1, chamber 8). 
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Appendix B: Experimental design and protocols 
 
Preparation of MES buffer 
 
MES buffer solution prepared by dissolving dried powdered of MES buffer (4.88 gr) in 100ml milli-Q 
water (5ml). MES buffer solution was adjusted to pH=6 by pH meter and distilled water added to it to 
give the final volume of 500ml. MES buffer solution sealed and  kept at 4◦C in a cold room for this 
experiment.  
Sigma pig mucus preparation 
Sigma pig mucin dried powder weight out (0.045 gr) and solubilized in 1 ml of MES buffer (100 
mM). The suspension left to stand on magnetic stirrer in a cold room (4 ◦C) for 24 hours. 
Sigma pig mucus + polymeric mucus preparation 
Sigma pig mucin (0.03 gr) + polymeric mucin (0.015) dried powder weight out and solubilized in 1 
ml of MES buffer (100 mM). The suspension left to stand on magnetic stirrer in a cold room (4 ◦C) 
for 24 hours. 
G-blocks preparation  
G-blocks dried powder (0.025 gr) weight out and solubilized in 1 ml of MES buffer (100 mM). The 
suspension gently stirred for 5 minute and left in a cold room (4 ◦C). 
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Preparation of G-blocks concentrations 
Method 1 
G-blocks (0.04 mg/ml) 
Beads stock: 2% 
Concentration 0.4 % → 1/5 dilution 
20 mg/ml G-blocks – 25 mg/ml G-blocks          [MES buffer + 20 mg/ml G-blocks] 
40 µl of G-blocks + 10 µl beads → 0.4 % beads in 20 mg/ml G-blocks → 5 µl into the mucus 
205 µl in mucus → 200 µl of mucus (2 types of mucin) + 5 µl beads diluted in G-blocks 
 
Method 2 
G-blocks (0.04 mg/ml) 
200 µl → 205 µl 
150 µl of 60 mg/ml mucin + 50 µl of 2 mg/ml G-blocks + 5 µl of beads (0.41 %) 
5 µl of beads (0.41 %) → 10 µl beads stock + 39 µl MES buffer 
G-blocks (0.5 mg/ml) 
200 µl → 205 µl 
150 µl of 60 mg/ml mucin + 50 µl of 160 mg/ml G-blocks + 5 µl of beads (0.41 %) 
5 µl of beads (0.41 %) → 10 µl beads stock + 39 µl MES buffer 
0.04 mg/ml = 40 µg/ml 
2 mg/ml → 160 µg/ml 
2 mg/ml → 1 + 115 → 100 µl + 1150 µl (MES buffer) → 1250 µl 0f 160 µg/ml 
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Table B.1: Experimental design for phase 1 of experiments (Carboxylate modified-nanoparticle) 
 Cover glass slide chamber     Nanoparticle      Mucus sample    Method of beads addition   G-blocks 
          Eight chamber                 2% w/w             45 mg/ml                Stirred/Unstirred            mg/ml 
            Chamber 1                  Carboxylate   Sigma pig mucus (200 µl)       Stirred                        - 
            Chamber 2                  Carboxylate   Sigma pig mucus (200 µl)       Unstirred                    - 
            Chamber 3                  Carboxylate   Sigma pig mucus (200 µl)       Stirred                      0.04  
            Chamber 4                  Carboxylate   Sigma pig mucus (200 µl)       Unstirred                  0.04 
            Chamber 5                  Carboxylate   SPM + PM mucus (200 µl)      Stirred                        - 
            Chamber 6                  Carboxylate   SPM + PM mucus (200 µl)      Unstirred                    - 
            Chamber 7                  Carboxylate   SPM + PM mucus (200 µl)      Stirred                      0.04 
            Chamber 8                  Carboxylate   SPM + PM mucus (200 µl)      Unstirred                  0.04 
 
 In Chambers 1, and 5, 5 µl of a mixture of beads-MES buffer were gently stirred in sigma pig 
mucus and in sigma pig mucus + polymeric mucus respectively. 
 In Chambers 2, and 6, 5 µl of a mixture of beads-MES buffer were added on top left side in 
sigma pig mucus and in sigma pig mucus + polymeric mucus respectively. 
 In Chambers 3, and 7, 5 µl of a mixture of beads-G-blocks were gently stirred in sigma pig 
mucus and in sigma pig mucus + polymeric mucus. 
 In Chambers 4, and 8, 5 µl of a mixture of beads-G-blocks were added on top left side in 
sigma pig mucus and in sigma pig mucus + polymeric mucus respectively. 
 
*The experiment performed in triplicate repeats. 
* G-blocks suspension made by method 1, (Preparation of G-blocks concentrations). 
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Phase 2 of experiments 
Table B.2: Experimental design for phase 2 of experiments (Carboxylate-modified nanoparticle) 
 Cover glass slide chamber     Nanoparticle      Mucus sample    Method of beads addition   G-blocks 
          Eight chamber                2% w/w             45 mg/ml                Stirred/Unstirred           mg/ml 
            Chamber 1                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04      
            Chamber 2                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04 
            Chamber 3                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04  
            Chamber 4                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04 
            Chamber 5                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04 
            Chamber 6                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04   
            Chamber 7                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04 
            Chamber 8                  Carboxylate   Sigma pig mucus (150 µl)       Stirred                   0.04 
 
*In Chambers 1, 2, 3, and 4, sigma pig mucus subjected to treat with G-blocks and nanoparticle 
suspensions (55 µl of mixture of beads-MES buffer) were gently stirred into mucus. 
*In Chambers 5, 6, 7, and 8, nanoparticles were treated with G-blocks (55 µl of mixture of beads-
G-blocks) and were gently stirred in sigma pig mucus. 
*G-blocks suspension was prepared by method 2, (Preparation of G-blocks concentrations). 
*Note that same procedure was used and performed for amine nanoparticles (Table 3). 
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Table B.3: Experimental design for phase 2 of experiments (Amine modified-nanoparticle) 
 Cover glass slide chamber     Nanoparticle      Mucus sample    Method of beads addition   G-blocks 
          Eight chamber                2% w/w             45 mg/ml                Stirred/Unstirred           mg/ml 
            Chamber 1                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04      
            Chamber 2                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04 
            Chamber 3                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04  
            Chamber 4                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04 
            Chamber 5                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04 
            Chamber 6                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04   
            Chamber 7                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04 
            Chamber 8                    Amine   Sigma pig mucus (150 µl)          Stirred                   0.04 
 
*In Chambers 1, 2, 3, and 4, sigma pig mucus subjected to treat with G-blocks and nanoparticle 
suspensions (55 µl of mixture of beads-MES buffer) were gently stirred into mucus. 
*In Chambers 5, 6, 7, and 8, nanoparticles were treated with G-blocks (55 µl of mixture of beads-
G-blocks) and were gently stirred in sigma pig mucus. 
*G-blocks suspension was prepared by method 2, (Preparation of G-blocks concentrations). 
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Appendix C: Confocal microscope setting  
 
The motion of amine and carboxylate modified nanoparticles were imaged with Leica 
microscope according to instruction given in Table D.1. 
 
                                          Table C.1: Confocal microscope operation set up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    Confocal laser scanning microscope 
           Model:  Leica TCS SP5 
Laser  Argon, 488 
Power 20 % 
Beam path setting FITC 
PMT PMT1 
Gain 572.2 v 
Image resolution 512×512 pixels 
Laser Argon, 488 
Power 20 % 
Beam path setting FITC 
PMT PMT1 
Acquisition mode XYT 
Time interval 73-ms 
Duration 2 min 
Objective HCXPLAPO CS 
63.0x 1.20 WATER 
UV 
Number of frame  512 
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Appendix D: Matlab pre difiend script 
 
The code was made by Astrid Bjorkoy for Catherine T. Nordgard in 2011. This script is used 
to convert all trajectories into mean square displacement (MSD) value in Matlab. Input and 
output file to Matlab was .txt. Alteratons was made from the orginal code concerning file 
source and saving positions, only to match the computer used for the work. 
Matlab R2009a was used at computer lab at NTNU. 
Function ParticleTracker 
 
 
% Prompt for lag time between frames 
% Promt for name of resultfile! 
prompt = {'Enter time interval:','Enter name of result file:'}; 
dlg_title = 'Input for Trajectory Calculations'; 
num_lines = 1; 
def = {'1','results.txt'}; 
answer = inputdlg(prompt,dlg_title,num_lines,def); 
 
timeinterval = str2double(answer{1}); 
filnavn = answer{2}; 
 
% Open the file with the trajectory data 
[File, Path] = uigetfile('*.txt','Open Trajectory file',... 
          'M:\Mikroskopi\Catherine Taylor\','MultiSelect','Off') 
 
s1 = char(strcat(Path,File)); 
fid = fopen(s1); 
 
k = 1; 
% Figure out what trajectories are in this file, put the names in 
% Nr.Trajectory and the number of frames for particle k in Particles 
while 1 
    tline = fgetl(fid); 
    if ~ischar(tline),   break,   end 
    if ~isempty(tline) 
        if tline(1) == '%' 
            nr = 0; 
            Nr(k).Trajectory = tline(4:end); 
            k = k+1; 
        else nr = nr+1; 
        end 
    else Particles(k-1) = nr;  
    end 
end 
fclose(fid); 
 
% Import the trajectory data and put data in newData1 
rawData1 = importdata(s1); 
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% For some simple files (such as a CSV or JPEG files), IMPORTDATA might 
% return a simple array.  If so, generate a structure so that the output 
% matches that from the Import Wizard. 
[unused,name] = fileparts(s1); %#ok 
newData1.(genvarname(name)) = rawData1; 
 
% Create new variables in the base workspace from those fields. 
vars = fieldnames(newData1); 
for i = 1:length(vars) 
    assignin('base', vars{i}, newData1.(vars{i})); 
end 
 
j = 1; 
pend = 0; 
 
% For each particle, calculate the msd's for each time step! 
% The frame number and (x,y) for each particle are between pstart and pend 
% in the data file newData1. 
for particle = 1:length(Particles) 
    pstart = pend + 1; 
    pend = pstart + (Particles(particle)-1); 
    % p is an array containing the frame numbers 
    p = newData1.(genvarname(name))(pstart:pend,1); 
    x = newData1.(genvarname(name))(pstart:pend,2); 
    y = newData1.(genvarname(name))(pstart:pend,3); 
    % maxstep is the maximum lag time possible for the particle 
    maxstep = p(end)-p(1); 
    for step = 1:maxstep 
        ave = [];  % vector of msd's 
        i = p(1);  % number of startframe 
        while i+step <= p(end) 
            % ignore frames missing! 
            if ~ismember(i,p) || ~ismember((i+step),p) 
            else 
                % find the correct position in p, x and y for i and i+step 
                i1 = find(p==i);  
                i2 = find(p==(i+step)); 
                new =((x(i1)-x(i2))^2 + (y(i1)-y(i2))^2); 
                ave = [new ave]; 
            end 
            i = i+1; 
        end 
        if ~isempty(ave) 
            msd(particle, step) = mean(ave); %mean msd for this step/lag time 
        end 
    end 
end 
   
 
% Save the data to a file: lag time in first column, data for the 
% particles in the other columns. 
 datafile = strcat(Path, filnavn); 
 fid = fopen(char(datafile),'a'); 
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 fprintf(fid,'%s', 'Step'); 
 for i = 1:length(Particles) 
     fprintf(fid,'\t %s',Nr(i).Trajectory); 
 end 
 fprintf(fid,'\n'); 
  
 % size(msd,2) is the maximum number of frames for the particles 
 % in the data file newData1 
 for i = 1:size(msd,2) 
     fprintf(fid,'%6.4f \t', i*timeinterval); 
     for j = 1:length(Particles) 
         % if there's data missing for this lag time, skip info! 
         % else save the result 
         if msd(j,i) == 0 fprintf(fid,'\t'); 
         else fprintf(fid,'%6.4f \t',msd(j,i)); 
         end 
     end 
     fprintf(fid,'\n'); 
 end 
 
  
end 
 
 
 
 
 
